При участии

russjcardiol

Российский кардиологический журнал

Russian Journal of Cardiology

1560-40712618-7620

«SILICEA-POLIGRAF» LLC

10.15829/1560-4071-2021-4541

russjcardiol-4541

Research Article

КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ

CLINICAL GUIDELINES

Гипертрофическая кардиомиопатия. Клинические рекомендации 2020

2020 Clinical practice guidelines for Hypertrophic cardiomyopathy

Габрусенко

С. А.

Gabrusenko

S. A.

cardiojournal@yandex.ru

Гудкова

А. Я.

Gudkova

A. Ya.

alexagood-1954@mail.ru

Козиолова

Н. А.

Koziolova

N. A.

Александрова

С. А.

Alexandrova

S. A.

Берсенева

М. И.

Berseneva

M. I.

Гордеев

М. Л.

Gordeev

M. L.

Дземeшкевич

С. Л.

Dzemeshkevich

S. L.

Заклязьминская

Е. В.

Zaklyazminskaya

E. V.

Иртюга

О. Б.

Irtyuga

O. B.

Каплунова

В. Ю.

Kaplunova

V. Yu.

Костарева

А. А.

Kostareva

A. A.

Крутиков

А. Н.

Krutikov

A. N.

Маленков

Д. А.

Malenkov

D. A.

Новикова

Т. Н.

Novikova

T. N.

Саидова

М. А.

Saidova

M. A.

Санакоев

М. К.

Sanakoev

M. K.

Стукалова

О. В.

Stukalova

O. V.

2021

09082021

26545414541

Copyright © Габрусенко С.А., Гудкова А.Я., Козиолова Н.А., Александрова С.А., Берсенева М.И., Гордеев М.Л., Дземeшкевич С.Л., Заклязьминская Е.В., Иртюга О.Б., Каплунова В.Ю., Костарева А.А., Крутиков А.Н., Маленков Д.А., Новикова Т.Н., Саидова М.А., Санакоев М.К., Стукалова О.В., 2021

2021

Габрусенко С.А., Гудкова А.Я., Козиолова Н.А., Александрова С.А., Берсенева М.И., Гордеев М.Л., Дземeшкевич С.Л., Заклязьминская Е.В., Иртюга О.Б., Каплунова В.Ю., Костарева А.А., Крутиков А.Н., Маленков Д.А., Новикова Т.Н., Саидова М.А., Санакоев М.К., Стукалова О.В.

Gabrusenko S.A., Gudkova A.Y., Koziolova N.A., Alexandrova S.A., Berseneva M.I., Gordeev M.L., Dzemeshkevich S.L., Zaklyazminskaya E.V., Irtyuga O.B., Kaplunova V.Y., Kostareva A.A., Krutikov A.N., Malenkov D.A., Novikova T.N., Saidova M.A., Sanakoev M.K., Stukalova O.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://russjcardiol.elpub.ru/jour/article/view/4541

Российское кардиологическое общество (РКО)

При участии

При участии: Ассоциации сердечно-сосудистых хирургов России (АССХ)

Одобрено Научно-практическим Советом Минздрава Российской Федерации

Президиум рабочей группы

Президиум рабочей группы: Габрусенко С. А., Гудкова А. Я.*, Козиолова Н. А.

Рабочая группа

Рабочая группа: Александрова С. А., Берсенева М. И., Гордеев М. Л., Дземeшкевич С. Л., Заклязьминская Е. В., Иртюга О. Б., Каплунова В. Ю., Костарева А. А., Крутиков А. Н., Маленков Д. А., Новикова Т. Н., Саидова М. А., Санакоев М. К., Стукалова О. В.

Russian Society of Cardiology (RSC)

With the participation

With the participation: Russian Association of Cardiovascular Surgeons

Endorsed by

Endorsed by: Research and Practical Council of the Ministry of Health of the Russian Federation

Task Force

Task Force: Gabrusenko S.A. (Chairman), Gudkova A.Ya.* (Chairman), Koziolova N.A. (Chairman), Alexandrova S.A., Berseneva M.I., Gordeev M.L., Dzemeshkevich S.L., Zaklyazminskaya E.V., Irtyuga O.B., Kaplunova V.Yu., Kostareva A.A., Krutikov A.N., Malenkov D.A., Novikova T.N., Saidova M.A., Sanakoev M.K., Stukalova O.V.

гипертрофическая кардиомиопатияобструктивная гипертрофическая кардиомиопатияфенокопии гипертрофической кардиомиопатиисаркомерные мутациисемейный генетический скринингвнезапная сердечная смертьстратификация рискажелудочковые нарушения ритмафибрилляция предсердийсептальная миоэктомиясептальная алкогольная аблацияобструкция выходного тракта левого желудочканагрузочные пробысистолическая дисфункциядиастолическая дисфункцияхроническая сердечная недостаточность

: hypertrophic cardiomyopathyobstructive hypertrophic cardiomyopathyhypertrophic cardiomyopathy phenocopiessarcomeric mutationsfamilial genetic screeningsudden cardiac deathrisk stratificationventricular arrhythmiasatrial fibrillationseptal myoectomyseptal alcohol ablationleft ventricular outlet tract obstructionexercise testssystolic dysfunctiondiastolic dysfunctionchronic heart failure

References1

Габрусенко С. А., Селезнёв Д. М., Наумов В. Г. Генетические аспекты гипертрофической кардиомиопатии (обзор литературы). Практикующий врач. 2000;18(2):2-5.

Gabrusenko SA, Seleznev DM, Naumov VG. Genetic aspects of hypertrophic cardiomyopathy (literature review). A medical practitioner. 2000;18(2):2-5.

Шляхто Е. В., Гудкова А. Я., Костарева А. А. Первичные кардиомиопатии, современное представление. Терапевтический архив. 2005;77(12):77-83.

Shlyakhto EV, Gudkova AYa, Kostareva AA. Primary cardiomyopathies, modern presentation. Therapeutic Archive. 2005;77(12):77-83.

Gersh BJ, Maron BJ, Bonow RO, et al.; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Failure Society of America; Heart Rhythm Society; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124(24):2761-96. doi:10.1161/CIR.0b013e318223e230.

Authors/Task Force members, Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733-79. doi:10.1093/eurheartj/ehu284.

Alfares AA, Kelly MA, McDermott G, et al. Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. Genet Med. 2015;17(11):880-8. doi:10.1038/gim.2014.205. Erratum in: Genet Med. 2015;17(4):319.

Coats CJ, Elliott PM. Genetic biomarkers in hypertrophic cardiomyopathy. Biomark Med. 2013;7(4):505-16. doi:10.2217/bmm.13.79.

Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet. 2004;363(9424):1881-91. doi:10.1016/S0140-6736(04)16358-7.

Kelly MA, Caleshu C, Morales A, et al. Adaptation and validation of the ACMG/AMP variant classification framework for MYH7-associated inherited cardiomyopathies: recommendations by ClinGen's Inherited Cardiomyopathy Expert Panel. Genet Med. 2018;20(3):351-9. doi:10.1038/gim.2017.218.

Kokado H, Shimizu M, Yoshio H, et al. Clinical features of hypertrophic cardiomyopathy caused by a Lys183 deletion mutation in the cardiac troponin I gene. Circulation. 2000;102(6):663-9. doi:10.1161/01.cir.102.6.663.

Kostareva A, Gudkova A, Sjöberg G, et al. Deletion in TNNI3 gene is associated with restrictive cardiomyopathy. Int J Cardiol. 2009;131(3):410-2. doi:10.1016/j.ijcard.2007.07.108.

Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002;287(10):1308-20. doi:10.1001/jama.287.10.1308.

Maron BJ, Maron MS, Maron BA, Loscalzo J. Moving Beyond the Sarcomere to Explain Heterogeneity in Hypertrophic Cardiomyopathy: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;73(15):1978-86. doi:10.1016/j.jacc.2019.01.061.

Mogensen J, Murphy RT, Kubo T, et al. Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;44(12):2315-25. doi:10.1016/j.jacc.2004.05.088.

Селезнёв Д. М., Габрусенко С. А., Парфенова Е. В. и др. Роль мутаций в гене тяжелой цепи сердечного бета-миозина в российской популяции больных с гипертрофической кардиомиопатией. Кардиология. 2005;45(4):15-20.

Seleznev DM, Gabrusenko SA, Parfenova EV, et al. The role of mutation in cardiac P-myosin heavy chain gene in a population of patients with hypertrophic cardiomyopathy in Russia. Kardiologiia. 2005;45(4):15-20.

Туральчук М. В., Новик Г. А., Гудкова А. Я. Особенности течения кардиомиопатий с рестриктивным фенотипом, обусловленных мутациями генов сердечного тропонина I и десмина, и алгоритмы их диагностики. Педиатрическая фармакология. 2011;8(4):112-6.

Turalchuk MV, Novik GA, Gudkova AYa. Features of the course of cardiomyopathies with a restrictive phenotype caused by mutations of the cardiac troponin I and desmin genes, and algorithms for their diagnosis. Pediatric pharmacology. 2011;8(4):112-6.

Burton D, Abdulrazzak H, Knott A, et al. Two mutations in troponin I that cause hypertrophic cardiomyopathy have contrasting effects on cardiac muscle contractility. Biochem J. 2002;362(Pt 2):443-51. doi:10.1042/0264-6021:3620443.

Zhou N, Qin S, Liu Y, et al. Whole-exome sequencing identifies rare compound heterozygous mutations in the MYBPC3 gene associated with severe familial hypertrophic cardiomyopathy. Eur J Med Genet. 2018;61(8):434-41. doi:10.1016/j.ejmg.2018.03.001.

Charron P, Forissier JF, Amara ME, et al. Accuracy of European diagnostic criteria for familial hypertrophic cardiomyopathy in a genotyped population. Int J Cardiol. 2003;90(1):33-8; discussion 38-40. doi:10.1016/s0167-5273(02)00534-x.

Lopes LR, Murphy C, Syrris P, et al. Use of high-throughput targeted exome-sequencing to screen for copy number variation in hypertrophic cardiomyopathy. Eur J Med Genet. 2015;58(11):611-6. doi:10.1016/j.ejmg.2015.10.001.

European Society of Cardiology (ESC); European Heart Rhythm Association (EHRA), Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace. 2013;15(8):1070-118. doi:10.1093/europace/eut206.

Hiemstra YL, Debonnaire P, van Zwet EW, et al. Development of and Progression of Overt Heart Failure in Nonobstructive Hypertrophic Cardiomyopathy. Am J Cardiol. 2018;122(4):656-62. doi:10.1016/j.amjcard.2018.04.038.

Ho CY, Day SM, Colan SD, et al.; HCMNet Investigators. The Burden of Early Phenotypes and the Influence of Wall Thickness in Hypertrophic Cardiomyopathy Mutation Carriers: Findings From the HCMNet Study. JAMA Cardiol. 2017;2(4):419-28. doi:10.1001/jamacardio.2016.5670.

Hodatsu A, Konno T, Hayashi K, et al. Compound heterozygosity deteriorates phenotypes of hypertrophic cardiomyopathy with founder MYBPC3 mutation: evidence from patients and zebrafish models. Am J Physiol Heart Circ Physiol. 2014;307(11):H1594-604. doi:10.1152/ajpheart.00637.2013.

Horimoto M, Yokota K, Inoue H, et al. Development of obstructive hypertrophic cardiomyopathy from nonobstructive hypertrophic cardiomyopathy. Am J Cardiol. 1998;82(3):403-5. doi:10.1016/s0002-9149(98)00337-3.

Ansari-Lari MA, Ali SZ. Fine-needle aspiration of abdominal fat pad for amyloid detection: a clinically useful test? Diagn Cytopathol. 2004;30(3):178-81. doi:10.1002/dc.10370.

Canepa M, Sorensen LL, Pozios I, et al. Comparison of clinical presentation, left ventricular morphology, hemodynamics, and exercise tolerance in obese versus nonobese patients with hypertrophic cardiomyopathy. Am J Cardiol. 2013;112(8):1182-9. doi:10.1016/j.amjcard.2013.05.070.

Charron P, Arad M, Arbustini E, et al.; European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2010;31(22):2715-26. doi:10.1093/eurheartj/ehq271.

Finocchiaro G, Magavern E, Sinagra G, et al. Impact of Demographic Features, Lifestyle, and Comorbidities on the Clinical Expression of Hypertrophic Cardiomyopathy. J Am Heart Assoc. 2017;6(12):e007161. doi:10.1161/JAHA.117.007161.

Bos JM, Ommen SR, Ackerman MJ. Genetics of hypertrophic cardiomyopathy: one, two, or more diseases? Curr Opin Cardiol. 2007;22(3):193-9. doi:10.1097/HCO.0b013e3280e1cc7f.

Richards S, Aziz N, Bale S, et al.; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-24. doi:10.1038/gim.2015.30.

Marian AJ, Braunwald E. Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circ Res. 2017;121(7):749-70. doi:10.1161/CIRCRESAHA.117.311059.

Бокерия Л. А., Гудкова А. Я., Созин С. Е. и др. Экспрессия генов матриксной металлопротеиназы-1 (ММР-1), тканевого ингибитора матриксных металлопротеиназ-1 (TIMP-1), коллагена I и III типов в миокарде больных идиопатической гипертрофической кардиомиопатией. Бюллетень НЦССХ им. А. Н. Бакулева РАМН. 2005;6(4):35-42.

Bokeria LA, Gudkova AYa, Sozin SE, et al. Expression of genes of matrix metalloproteinase-1 (MMP-1), tissue inhibitor of matrix metalloproteinases-1 (TIMP-1), and type I and III collagen in the myocardium of patients with idiopathic hypertrophic cardiomyopathy. Bulletin of the A. N. Bakulev National Research Center of the Russian Academy of Sciences. 2005;6(4):35-42.

Гудкова А. Я., Рыбакова М. Г., Шляхто Е. В., Бокерия Л. А. Гипертрофическая кардиомиопатия. Клинико-морфологические сопоставления. Архив патологии. 2012;74(4):8-11.

Gudkova AYa, Rybakova MG, Shlyakhto EV, Bokeria LA. Hypertrophic cardiomyopathy. Clinical and morphological comparisons. Archive of Pathology. 2012;74(4):8-11.

Гудкова А. Я. Характеристика течения обструктивной гипертрофической кардиомиопатии у взрослых (обзор литературы и результаты собственных исследований). Артериальная гипертензия. 2008;14(2), Приложение 2:39-49.

Gudkova AYa. Characteristics of the course of obstructive hypertrophic cardiomyopathy in adults (literature review and results of own research). Arterial hypertension. 2008;14(2), Appendix 2:39-49.

Гудкова А. Я., Шляхто Е. В. Клеточные механизмы гипертрофии миокарда при гипертрофической кардиомиопатии и эссенциальной артериальной гипертензии. Артериальная гипертензия. 2008;14(4):373-80.

Gudkova AYa, Shlyakhto EV. Cellular mechanisms of myocardial hypertrophy in hypertrophic cardiomyopathy and essential arterial hypertension. Arterial hypertension. 2008;14(4):373-80.

Shliakhto EV, Bokeriia LA, Rybakova MG, et al. Cellular aspects of hypertrophic cardiomyopathy pathogenesis: the role of cardiomyocyte polyploidy and activation of the proliferating cell nuclear antigen in the myocardium. Tsitologiia. 2007;49(10):817-23.

Frustaci A, Russo MA, Chimenti C. Diagnostic contribution of left ventricular endomyocardial biopsy in patients with clinical phenotype of hypertrophic cardiomyopathy. Hum Pathol. 2013;44(1):133-41. doi:10.1016/j.humpath.2012.04.023.

Leone O, Veinot JP, Angelini A, et al. 2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol. 2012;21(4):245-74. doi:10.1016/j.carpath.2011.10.001.

Philipson DJ, DePasquale EC, Yang EH, Baas AS. Emerging pharmacologic and structural therapies for hypertrophic cardiomyopathy. Heart Fail Rev. 2017;22(6):879-88. doi:10.1007/s10741-017-9648-x.

Roberts R, Sigwart U. Current concepts of the pathogenesis and treatment of hypertrophic cardiomyopathy. Circulation. 2005;112(2):293-6. doi:10.1161/01.CIR.0000146788.30724.0A.

Varnava AM, Elliott PM, Sharma S, et al. Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart. 2000;84(5):476-82. doi:10.1136/heart.84.5.476.

Зайцев В. В., Гурщенков А. В., Митрофанова Л. Б. и др. Клиническое значение различных методов оценки миокардиального фиброза при гипертрофической кардиомиопатии. Кардиология. 2020;60(3):44-50. doi:10.18087/cardio.2020.3.n561.

Zaitsev VV, Gurshchenkov AV, Mitrofanova LB, et al. Clinical significance of different assesment methods of myocardial fibrosis in patients with hypertrophic cardiomyopathy. Kardiologiia. 2020;60(3):44-50. doi:10.18087/cardio.2020.3.n561.

Arbustini E, Narula N, Dec GW, et al. The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: endorsed by the World Heart Federation. J Am Coll Cardiol. 2013;62(22):2046-72. doi:10.1016/j.jacc.2013.08.1644. Erratum in: J Am Coll Cardiol. 2014;63(2):191-4.

Barcia G, Rachid M, Magen M, et al. Pitfalls in molecular diagnosis of Friedreich ataxia. Eur J Med Genet. 2018;61(8):455-8. doi:10.1016/j.ejmg.2018.03.004.

Bokhari S, Castaño A, Pozniakoff T, et al. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6(2):195-201. doi:10.1161/CIRCIMAGING.112.000132.

Charron P, Villard E, Sébillon P, et al. Danon's disease as a cause of hypertrophic cardiomyopathy: a systematic survey. Heart. 2004;90(8):842-6. doi:10.1136/hrt.2003.029504.

Cook A, Giunti P. Friedreich's ataxia: clinical features, pathogenesis and management. Br Med Bull. 2017;124(1):19-30. doi:10.1093/bmb/ldx034.

D'Souza A, Theis JD, Vrana JA, et al. Localized insulin-derived amyloidosis: a potential pitfall in the diagnosis of systemic amyloidosis by fat aspirate. Am J Hematol. 2012;87(11):E131-2. doi:10.1002/ajh.23334.

Dubrey SW, Hawkins PN, Falk RH. Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart. 2011;97(1):75-84. doi:10.1136/hrt.2009.190405.

Frustaci A, Chimenti C, Doheny D, Desnick RJ. Evolution of cardiac pathology in classic Fabry disease: Progressive cardiomyocyte enlargement leads to increased cell death and fibrosis, and correlates with severity of ventricular hypertrophy‬‬‬‬‬‬‬‬. Int J Cardiol. 2017;248:257-62. doi:10.1016/j.ijcard.2017.06.079.

Monserrat L, Gimeno-Blanes JR, Marín F, et al. Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2007;50(25):2399-403. doi:10.1016/j.jacc.2007.06.062.

Planté-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011;10(12):1086-97. doi:10.1016/S1474-4422(11)70246-0.

Quarta CC, Guidalotti PL, Longhi S, et al. Defining the diagnosis in echocardiographically suspected senile systemic amyloidosis. JACC Cardiovasc Imaging. 2012;5(7):755-8. doi:10.1016/j.jcmg.2012.02.015.

RDTF Report: European reference networks in the field of Rare Diseases: State of the art and Future Directions. Jul, 2008. http://www.eucerd.eu/upload/file/Publication/RDTFERN2008.pdf.

Sado DM, White SK, Piechnik SK, et al. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging. 2013;6(3):392-8. doi:10.1161/CIRCIMAGING.112.000070.

Tsai SB, Seldin DC, Wu H, et al. Myocardial infarction with "clean coronaries" caused by amyloid light-chain AL amyloidosis: a case report and literature review. Amyloid. 2011;18(3):160-4. doi:10.3109/13506129.2011.571319.

Vogelsberg H, Mahrholdt H, Deluigi CC, et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol. 2008;51(10):1022-30. doi:10.1016/j.jacc.2007.10.049.

Wilkinson JD, Lowe AM, Salbert BA, et al. Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: a study from the Pediatric Cardiomyopathy Registry. Am Heart J. 2012;164(3):442-8. doi:10.1016/j.ahj.2012.04.018.

Yang Z, Vatta M. Danon disease as a cause of autophagic vacuolar myopathy. Congenit Heart Dis. 2007;2(6):404-9. doi:10.1111/j.1747-0803.2007.00132.x.

Yang Z, McMahon CJ, Smith LR, et al. Danon disease as an underrecognized cause of hypertrophic cardiomyopathy in children. Circulation. 2005;112(11):1612-7. doi:10.1161/CIRCULATIONAHA.105.546481.

Ibrahim M, Rao C, Ashrafian H, et al. Modern management of systolic anterior motion of the mitral valve. Eur J Cardiothorac Surg. 2012;41(6):1260-70. doi:10.1093/ejcts/ezr232.

Deng L, Huang X, Yang C, et al. Numerical simulation study on systolic anterior motion of the mitral valve in hypertrophic obstructive cardiomyopathy. Int J Cardiol. 2018;266:167-73. doi:10.1016/j.ijcard.2018.01.062.

Manabe S, Kasegawa H, Arai H, Takanashi S. Management of systolic anterior motion of the mitral valve: a mechanism-based approach. Gen Thorac Cardiovasc Surg. 2018;66(7):379-89. doi:10.1007/s11748-018-0915-0.

Ro R, Halpern D, Sahn DJ, et al. Vector flow mapping in obstructive hypertrophic cardiomyopathy to assess the relationship of early systolic left ventricular flow and the mitral valve. J Am Coll Cardiol. 2014;64(19):1984-95. doi:10.1016/j.jacc.2014.04.090.

Hymel BJ, Townsley MM. Echocardiographic assessment of systolic anterior motion of the mitral valve. Anesth Analg. 2014;118(6):1197-201. doi:10.1213/ANE.0000000000000196.

Sherrid MV, Gunsburg DZ, Moldenhauer S, Pearle G. Systolic anterior motion begins at low left ventricular outflow tract velocity in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2000;36(4):1344-54. doi:10.1016/s0735-1097(00)00830-5.

Silbiger JJ. Abnormalities of the Mitral Apparatus in Hypertrophic Cardiomyopathy: Echocardiographic, Pathophysiologic, and Surgical Insights. J Am Soc Echocardiogr. 2016;29(7):622-39. doi:10.1016/j.echo.2016.03.003.

Shah JS, Esteban MT, Thaman R, et al. Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy. Heart. 2008;94(10):1288-94. doi:10.1136/hrt.2007.126003.

Geske JB, Sorajja P, Ommen SR, Nishimura RA. Variability of left ventricular outflow tract gradient during cardiac catheterization in patients with hypertrophic cardiomyopathy. JACC Cardiovasc Interv. 2011;4(6):704-9. doi:10.1016/j.jcin.2011.02.014.

Efthimiadis GK, Pagourelias ED, Parcharidou D, et al. Clinical characteristics and natural history of hypertrophic cardiomyopathy with midventricular obstruction. Circ J. 2013;77(9):2366-74. doi:10.1253/circj.cj-12-1561.

Minami Y, Kajimoto K, Terajima Y, et al. Clinical implications of midventricular obstruction in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2011;57(23):2346-55. doi:10.1016/j.jacc.2011.02.033.

Yan LR, Zhao SH, Wang HY, et al. Clinical characteristics and prognosis of 60 patients with midventricular obstructive hypertrophic cardiomyopathy. J Cardiovasc Med (Hagerstown). 2015;16(11):751-60. doi:10.2459/JCM.0000000000000163.

Hang D, Schaff HV, Ommen SR, et al. Combined transaortic and transapical approach to septal myectomy in patients with complex hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg. 2018;155(5):2096-102. doi:10.1016/j.jtcvs.2017.10.054.

Pacheco Claudio C, Quesada O, Pepine CJ, Noel Bairey Merz C. Why names matter for women: MINOCA/INOCA (myocardial infarction/ischemia and no obstructive coronary artery disease). Clin Cardiol. 2018;41(2):185-93. doi:10.1002/clc.22894.

Аверкина Н. В., Габрусенко С. А., Овчинников А. Г. и др. Оценка перфузии миокарда у больных с гипертрофической кардиомиопатией в сопоставлении с клиническими и эхокардиографическими данными. Терапевтический архив. 2003;78(4):20-5.

Averkina NV, Gabrusenko SA, Ovchinnikov AG, et al. Assessment of myocardial perfusion in patients with hypertrophic cardiomyopathy in comparison with clinical and echocardiographic data. Terapevticheskii arkhiv. 2003;78(4):20-5.

Аверков О. В., Барбараш О. Л., Бойцов С. А. и др. Дифференцированный подход в диагностике, формулировке диагноза, ведении больных и статистическом учете инфаркта миокарда 2 типа (согласованная позиция). Российский кардиологический журнал. 2019;(6):7-21. doi:10.15829/1560-4071-2019-6-7-21.

Averkov OV, Barbarash OL, Boytsov SA, et al. Differentiated approach in diagnostics, diagnosis formulation, case management and statistical accounting of type 2 myocardial infarction (Position Paper). Russian Journal of Cardiology. 2019;(6):7-21. doi:10.15829/1560-4071-2019-6-7-21.

Каплунова В. Ю., Шакарьянц В. А., Кожевникова М. В. и др. Гипертрофическая кардиомиопатия и ишемическая болезнь сердца. Варианты сочетанной патологии. Кардиология. 2017;57(12):16-24. doi:10.18087/cardio.2017.12.10062.

Kaplunova VYu, Shakaryants GA, Kozhevnikova MV, et al. Hypertrophic Cardiomyopathy and Ischemic Heart Disease. Variants of Combination Pathology. Kardiologiia. 2017;57(12):16-24. doi:10.18087/cardio.2017.12.10062.

Костин С. И. Морфологические и морфометрические особенности гипертрофической кардиомиопатии. Архив патологии. 1989;51(1):47-52.

Kostin SI. Morphological and morphometric features of hypertrophic cardiomyopathy. Archive of Pathology. 1989;51(1):47-52.

Мухарлямов Н. Кардиомиопатии. Москва, 1990. с.283. ISBN 5-225-02119-0.

Muharlyamov N. Cardiomyopathy. Moscow, 1990. p. 283. ISBN 5-225-02119-0.

Aletras AH, Tilak GS, Hsu LY, Arai AE. Heterogeneity of intramural function in hypertrophic cardiomyopathy: mechanistic insights from MRI late gadolinium enhancement and high-resolution displacement encoding with stimulated echoes strain maps. Circ Cardiovasc Imaging. 2011;4(4):425-34. doi:10.1161/CIRCIMAGING.110.958751.

Camici PG, Olivotto I, Rimoldi OE. The coronary circulation and blood flow in left ventricular hypertrophy. J Mol Cell Cardiol. 2012;52(4):857-64. doi:10.1016/j.yjmcc.2011.08.028.

Einarsen E, Cramariuc D, Lønnebakken MT, et al. Comparison of Frequency of Ischemic Cardiovascular Events in Patients With Aortic Stenosis With Versus Without Asymmetric Septal Hypertrophy (from the SEAS Trial). Am J Cardiol. 2017;119(7):1082-7. doi:10.1016/j.amjcard.2016.11.064.

Foà A, Agostini V, Rapezzi C, et al. Histopathological comparison of intramural coronary artery remodeling and myocardial fibrosis in obstructive versus end-stage hypertrophic cardiomyopathy. Int J Cardiol. 2019;291:77-82. doi:10.1016/j.ijcard.2019.03.060.

Kwon DH, Smedira NG, Rodriguez ER, et al. Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: correlation with histopathology and prevalence of ventricular tachycardia. J Am Coll Cardiol. 2009;54(3):242-9. doi:10.1016/j.jacc.2009.04.026.

Maron MS, Olivotto I, Maron BJ, et al. The case for myocardial ischemia in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2009;54(9):866-75. doi:10.1016/j.jacc.2009.04.072.

Mundhenke M, Schwartzkopff B, Strauer BE. Structural analysis of arteriolar and myocardial remodelling in the subendocardial region of patients with hypertensive heart disease and hypertrophic cardiomyopathy. Virchows Arch. 1997;431(4):265-73. doi:10.1007/s004280050098.

Nakamura T, Sakamoto K, Yamano T, et al. Increased plasma brain natriuretic peptide level as a guide for silent myocardial ischemia in patients with non-obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;39(10):1657-63. doi:10.1016/s0735-1097(02)01813-2.

Raphael CE, Cooper R, Parker KH, et al. Mechanisms of Myocardial Ischemia in Hypertrophic Cardiomyopathy: Insights From Wave Intensity Analysis and Magnetic Resonance. J Am Coll Cardiol. 2016;68(15):1651-60. doi:10.1016/j.jacc.2016.07.751.

Sciagrà R, Calabretta R, Cipollini F, et al. Myocardial blood flow and left ventricular functional reserve in hypertrophic cardiomyopathy: a 13NH3 gated PET study. Eur J Nucl Med Mol Imaging. 2017;44(5):866-75. doi:10.1007/s00259-016-3603-2.

Shin YJ, Lee JH, Yoo JY, et al. Clinical significance of evaluating coronary atherosclerosis in adult patients with hypertrophic cardiomyopathy who have chest pain. Eur Radiol. 2019;29(9):4593-602. doi:10.1007/s00330-018-5951-8.

Liu W, Sun D, Yang J. Diastolic Dysfunction of Hypertrophic Cardiomyopathy Genotype-Positive Subjects Without Hypertrophy Is Detected by Tissue Doppler Imaging: A Systematic Review and Meta-analysis. J Ultrasound Med. 2017;36(10):2093-103. doi:10.1002/jum.14250.

Covella M, Rowin EJ, Hill NS, et al. Mechanism of Progressive Heart Failure and Significance of Pulmonary Hypertension in Obstructive Hypertrophic Cardiomyopathy. Circ Heart Fail. 2017;10(4):e003689. doi:10.1161/CIRCHEARTFAILURE.116.003689.

Germans T, Rüssel IK, Götte MJ, et al. How do hypertrophic cardiomyopathy mutations affect myocardial function in carriers with normal wall thickness? Assessment with cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2010;12(1):13. doi:10.1186/1532-429X-12-13.

Huang X, Yue Y, Wang Y, et al. Assessment of left ventricular systolic and diastolic abnormalities in patients with hypertrophic cardiomyopathy using real-time three-dimensional echocardiography and two-dimensional speckle tracking imaging. Cardiovasc Ultrasound. 2018;16(1):23. doi:10.1186/s12947-018-0142-y.

Matsumura Y, Elliott PM, Virdee MS, et al. Left ventricular diastolic function assessed using Doppler tissue imaging in patients with hypertrophic cardiomyopathy: relation to symptoms and exercise capacity. Heart. 2002;87(3):247-51. doi:10.1136/heart.87.3.247.

Бокерия Л. А., Борисов К. В., Синев А. Ф. Улучшение диастолической функции левого и правого желудочков сердца после хирургической коррекции гипертрофической обструктивной кардиомиопатии при помощи оригинального способа. Грудная и сердечно-сосудистая хирургия. 1999;(4):4-10.

Bokeria LA, Borisov KV, Sinev AF. Improvement of diastolic function of the left and right ventricles of the heart after surgical correction of hypertrophic obstructive cardiomyopathy using an original method. Russian Journal of Thoracic and Cardiovascular Surgery. 1999;(4):4-10.

Harris KM, Spirito P, Maron MS, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation. 2006;114(3):216-25. doi:10.1161/CIRCULATIONAHA.105.583500.

Biagini E, Spirito P, Rocchi G, et al. Prognostic implications of the Doppler restrictive filling pattern in hypertrophic cardiomyopathy. Am J Cardiol. 2009;104(12):1727-31. doi:10.1016/j.amjcard.2009.07.057.

Bravo PE, Luo HC, Pozios I, et al. Late gadolinium enhancement confined to the right ventricular insertion points in hypertrophic cardiomyopathy: an intermediate stage phenotype? Eur Heart J Cardiovasc Imaging. 2016;17(3):293-300. doi:10.1093/ehjci/jev154.

100

Fernández A, Vigliano CA, Casabé JH, et al. Comparison of prevalence, clinical course, and pathological findings of left ventricular systolic impairment versus normal systolic function in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2011;108(4):548-55. doi:10.1016/j.amjcard.2011.03.083.

101

Melacini P, Basso C, Angelini A, et al. Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy. Eur Heart J. 2010;31(17):2111-23. doi:10.1093/eurheartj/ehq136.

102

Maron MS, Hauser TH, Dubrow E, et al. Right ventricular involvement in hypertrophic cardiomyopathy. Am J Cardiol. 2007;100(8):1293-8. doi:10.1016/j.amjcard.2007.05.061.

103

Falcone DM, Moore D, Lambert EC. Idiopathic hypertrophic cardiomyopathy involving the right ventricle. Am J Cardiol. 1967;19(5):735-40. doi:10.1016/0002-9149(67)90480-8.

104

Shimizu M, Kawai H, Yokota Y, Yokoyama M. Echocardiographic assessment of right ventricular obstruction in hypertrophic cardiomyopathy. Circ J. 2003;67(10):855-60. doi:10.1253/circj.67.855.

105

Бокерия Л. А., Борисов К. В. Обструктивная гипертрофическая кардиомиопатия: методы хирургической коррекции. Грудная и сердечно-сосудистая хирургия. 1997;(1):61-5.

Bokeria LA, Borisov KV. Obstructive hypertrophic cardiomyopathy: methods of surgical correction. Thoracic and cardiovascular surgery. Russian Journal of Thoracic and Cardiovascular Surgery. 1997;(1):61-5.

106

Бокерия Л. А., Борисов К. В., Синев А. Ф. и др. Результаты медикаментозного и хирургического лечения гипертрофической кардиомиопатии с обструкцией выводных отделов левого и правого желудочков сердца. Грудная и сердечно-сосудистая хирургия. 2004;2:4-9.

Bockeria LA, Borisov KV, Sinew AF, et al. Results of medical and surgical treatments for hypertrophic cardiomyopathy with obstruction of the left and right ventricular outflow tracts. Russian Journal of Thoracic and Cardiovascular Surgery. 2004;2:4-9.

107

Бокерия Л. А., Борисов К. В., Синев А. Ф., Шевердина В. В. Хирургическая коррекция ранее неоперабельных форм гипертрофической обструктивной кардиомиопатии. Грудная и сердечно-сосудистая хирургия. 1999;(6):130-6.

Bokeria LA, Borisov KV, Sinev AF, Sheverdina VV. Surgical correction of previously inoperable forms of hypertrophic obstructive cardiomyopathy. Russian Journal of Thoracic and Cardiovascular Surgery. 1999;(6):130-6.

108

Pagourelias ED, Efthimiadis GK, Parcharidou DG, et al. Prognostic value of right ventricular diastolic function indices in hypertrophic cardiomyopathy. Eur J Echocardiogr. 2011;12(11):809-17. doi:10.1093/ejechocard/jer126.

109

Shah JP, Yang Y, Chen S, et al. Prevalence and Prognostic Significance of Right Ventricular Dysfunction in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol. 2018;122(11):1932-8. doi:10.1016/j.amjcard.2018.08.043.

110

Кактурский Л. Внезапная смерть (клиническая морфология). Москва, 2000. с.126. ISBN 5-93649-001-7.

Kaktursky L. Sudden death (clinical morphology). Moscow, 2000. p. 126. ISBN 5-93649-001-7.

111

Ревишвили А. Ш., Бойцов С. А., Давтян К. В. и др. Клинические рекомендации по проведению электрофизиологических исследований, катетерной абляции и применению имплантируемых антиаритмических устройств. Москва, 2017. с. 701. https://vnoa.ru/upload/Recomendation_2017_30_10_2017_HR.pdf. ISBN 978-5-9500922-0-6.

Revishvili ASh, Boytsov SA, Davtyan KV, et al. Clinical recommendations for conducting electrophysiological studies, catheter ablation, and the use of implantable antiarrhythmic devices. Moscow, 2017. p. 701. https://vnoa.ru/upload/Recomendation_2017_30_10_2017_HR.pdf. ISBN 978-5-9500922-0-6.

112

Adabag AS, Casey SA, Kuskowski MA, et al. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;45(5):697-704. doi:10.1016/j.jacc.2004.11.043.

113

Zipes DP, Camm AJ, Borggrefe M, et al.; American College of Cardiology; American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace. 2006;8(9):746-837. doi:10.1093/europace/eul108.

114

Czosek RJ, Jefferies JL, Khoury PR, et al. Arrhythmic Burden and Ambulatory Monitoring of Pediatric Patients with Cardiomyopathy. Pacing Clin Electrophysiol. 2016;39(5):443-51. doi:10.1111/pace.12835.

115

Desai M, Mentias A. Risk stratification in hypertrophic cardiomyopathy. Aging (Albany NY). 2019;11(6):1617-8. doi:10.18632/aging.101895.

116

Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol. 2000;36(7):2212-8. doi:10.1016/s0735-1097(00)01003-2.

117

Goyal V, Jassal DS, Dhalla NS. Pathophysiology and prevention of sudden cardiac death. Can J Physiol Pharmacol. 2016;94(3):237-44. doi:10.1139/cjpp-2015-0366.

118

Marrakchi S, Kammoun I, Bennour E, et al. Risk stratification in hypertrophic cardiomyopathy. Herz. 2020;45(1):50-64. [In English]. doi:10.1007/s00059-018-4700-8.

119

Weissler-Snir A, Adler A, Williams L, et al. Prevention of sudden death in hypertrophic cardiomyopathy: bridging the gaps in knowledge. Eur Heart J. 2017;38(22):1728-37. doi:10.1093/eurheartj/ehw268.

120

Weissler-Snir A, Chan RH, Adler A, et al. Usefulness of 14-Day Holter for Detection of Nonsustained Ventricular Tachycardia in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol. 2016;118(8):1258-63. doi:10.1016/j.amjcard.2016.07.043.

121

Goff ZD, Calkins H. Sudden death related cardiomyopathies – Hypertrophic cardiomyopathy. Prog Cardiovasc Dis. 2019;62(3):212-6. doi:10.1016/j.pcad.2019.04.001.

122

Bois JP, Adams JC, Kumar G, et al. Relation Between Temperature Extremes and Symptom Exacerbation in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol. 2016;117(6):961-5. doi:10.1016/j.amjcard.2015.12.046.

123

Haghjoo M, Faghfurian B, Taherpour M, et al. Predictors of syncope in patients with hypertrophic cardiomyopathy. Pacing Clin Electrophysiol. 2009;32(5):642-7. doi:10.1111/j.1540-8159.2009.02338.x.

124

Seggewiß H, Koljaja-Batzner A, Seggewiß K, Meesmann M. Synkope bei hypertropher (obstruktiver) Kardiomyopathie [Syncope in hypertrophic (obstructive) cardiomyopathy]. Herzschrittmacherther Elektrophysiol. 2018;29(2):178-82. [In German]. doi:10.1007/s00399-018-0567-x.

125

Williams L, Frenneaux M. Syncope in hypertrophic cardiomyopathy: mechanisms and consequences for treatment. Europace. 2007;9(9):817-22. doi:10.1093/europace/eum093.

126

Farhad H, Seidelmann SB, Vigneault D, et al. Left Atrial structure and function in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. J Cardiovasc Magn Reson. 2017;19(1):107. doi:10.1186/s12968-017-0420-0.

127

Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol. 2008;51(8):802-9. doi:10.1016/j.jacc.2007.09.064.

128

Philipson DJ, Rader F, Siegel RJ. Risk factors for atrial fibrillation in hypertrophic cardiomyopathy. Eur J Prev Cardiol. 2019:2047487319828474. doi:10.1177/2047487319828474.

129

Garg L, Gupta M, Sabzwari SRA, et al. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management. Heart Fail Rev. 2019;24(2):189-97. doi:10.1007/s10741-018-9752-6.

130

Killu AM, Park JY, Sara JD, et al. Cardiac resynchronization therapy in patients with end-stage hypertrophic cardiomyopathy. Europace. 2018;20(1):82-8. doi:10.1093/europace/euw327.

131

Kirchhof P, Benussi S, Kotecha D, et al.; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-962. doi:10.1093/eurheartj/ehw210.

132

Maron BJ, Rowin EJ, Udelson JE, Maron MS. Clinical Spectrum and Management of Heart Failure in Hypertrophic Cardiomyopathy. JACC Heart Fail. 2018;6(5):353-63. doi:10.1016/j.jchf.2017.09.011.

133

Seferović PM, Polovina M, Bauersachs J, et al. Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21(5):553-76. doi:10.1002/ejhf.1461.

134

Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation. 2000;102(8):858-64. doi:10.1161/01.cir.102.8.858.

135

Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65(12):1249-54. doi:10.1016/j.jacc.2015.01.019.

136

Amano Y, Kitamura M, Takayama M, et al. MRI classification of asymmetric septal hypertrophic cardiomyopathy and its relation to the presence of risk factors. Int J Cardiovasc Imaging. 2012;28(8):2019-25. doi:10.1007/s10554-012-0034-4.

137

Geske JB, Ommen SR, Gersh BJ. Hypertrophic Cardiomyopathy: Clinical Update. JACC Heart Fail. 2018;6(5):364-75. doi:10.1016/j.jchf.2018.02.010.

138

Дземешкевич С. Л., Фролова Ю. В., Ким С. Ю. и др. Анатомические и морфологические признаки диффузно-генерализованной формы гипертрофической кардиомиопатии. Российский кардиологический журнал. 2015;(5):58-63. doi:10.15829/1560-4071-2015-5-58-63.

Dzemeshkevich SL, Frolova YuV, Kim SYu, et al. Anatomic and morphological signs of a diffuse-generalized hypertrophic cardiomyopathy. Russian Journal of Cardiology. 2015;(5):58-63. doi:10.15829/1560-4071-2015-5-58-63.

139

Gudkova A, Kostareva A, Sjoberg G, et al. Diagnostic challenge in desmin cardiomyopathy with transformation of clinical phenotypes. Pediatr Cardiol. 2013;34(2):467-70. doi:10.1007/s00246-012-0312-x.

140

Rowin EJ, Maron MS, Chan RH, et al. Interaction of Adverse Disease Related Pathways in Hypertrophic Cardiomyopathy. Am J Cardiol. 2017;120(12):2256-64. doi:10.1016/j.amjcard.2017.08.048.

141

Габрусенко С. А., Сафрыгина Ю. В., Овчинников А. Г. и др. Клинико-гемодинамический статус и сердечные натрийуретические пептиды в плазме больных гипертрофической кардиомиопатией. Кардиологический вестник (Бюллетень РКНПК). 2006;1(2):25-31.

Gabrusenko SA, Safrygina YuV, Ovchinnikov AG, et al. Clinical and hemodynamic status and cardiac natriuretic peptides in the plasma of patients with hypertrophic cardiomyopathy. Cardiological Bulletin (Bulletin of the RKNPC). 2006;1(2):25-31.

142

Стрельцова А. А., Гудкова А. Я., Костарева А. А. Фибрилляция предсердий при гипертрофической кардиомиопатии: современные аспекты эпидемиологии, факторов риска, патогенеза и фармакотерапии. Consilium Medicum. 2018;20(5):34-9. doi:10.26442/2075-1753_2018.5.34-39.

Streltsova AA, Gudkova AYa, Kostareva AA. Atrial fibrillation in hypertrophic cardiomyopathy: modern aspects of epidemiology, risk factors, pathogenesis and pharmacotherapy. Consilium Medicum. 2018;20(5):34-9.

143

Стрельцова А. А., Гудкова А. Я., Полякова А. А. и др. Полиморфный вариант rs1739843 гена белка теплового шока 7 (HSPB7) и его связь с вариантами клинического течения и исходами у пациентов с гипертрофической кардиомиопатией (результаты 10-летнего наблюдения). Российский кардиологический журнал. 2019;(10):7-15. doi:10.15829/1560-4071-2019-10-7-15.

Streltsova AA, Gudkova AY, Poliakova AA, et al. Polymorphic variant rs1739843 of heat shock protein beta-7 (HSPB7) gene and its relationship with on clinical profile and outcomes in patients with hypertrophic cardiomyopathy (results of a 10-year follow-up). Russian Journal of Cardiology. 2019;(10):7-15. doi:10.15829/1560-4071-2019-10-7-15.

144

Binder J, Ommen SR, Gersh BJ, et al. Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: septal morphological features predict the presence of myofilament mutations. Mayo Clin Proc. 2006;81(4):459-67. doi:10.4065/81.4.459.

145

Elliott P, Spirito P. Prevention of hypertrophic cardiomyopathy-related deaths: theory and practice. Heart. 2008;94(10):1269-75. doi:10.1136/hrt.2008.154385.

146

Elliott PM, Gimeno JR, Thaman R, et al. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart. 2006;92(6):785-91. doi:10.1136/hrt.2005.068577.

147

Kawai C, Sakurai T, Fujiwara H, et al. Hypertrophic obstructive and non-obstructive cardiomyopathy in Japan. Diagnosis of the disease with special reference to endomyocardial catheter biopsy. Eur Heart J. 1983;4, Suppl F:121-5. doi:10.1093/eurheartj/4.suppl_f.121.

148

Kitaoka H, Kuwahara T, Nishida K, et al. Hypertrophic cardiomyopathy with progression from apical hypertrophy to asymmetrical septal hypertrophy: a case report. J Cardiol. 2005;45(4):155-9.

149

Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol. 1995;26(7):1699-708. doi:10.1016/0735-1097(95)00390-8.

150

Maron BJ, Olivotto I, Bellone P, et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;39(2):301-7. doi:10.1016/s0735-1097(01)01727-2.

151

Thaman R, Gimeno JR, Reith S, et al. Progressive left ventricular remodeling in patients with hypertrophic cardiomyopathy and severe left ventricular hypertrophy. J Am Coll Cardiol. 2004;44(2):398-405. doi:10.1016/j.jacc.2004.01.054.

152

Lancellotti P, Pellikka PA, Budts W, et al. The Clinical Use of Stress Echocardiography in Non-Ischaemic Heart Disease: Recommendations from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr. 2017;30(2):101-38. doi:10.1016/j.echo.2016.10.016.

153

Parato VM, Antoncecchi V, Sozzi F, et al.; Italian Chapter of ISCU. Echocardiographic diagnosis of the different phenotypes of hypertrophic cardiomyopathy. Cardiovasc Ultrasound. 2016;14(1):30. doi:10.1186/s12947-016-0072-5.

154

Lambiase PD, Barr C, Theuns DA, et al.; EFFORTLESS Investigators. Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry. Eur Heart J. 2014;35(25):1657-65. doi:10.1093/eurheartj/ehu112.

155

Ponikowski P, Voors AA, Anker SD, et al.; Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975. doi:10.1002/ejhf.592.

156

Maron BJ, McKenna WJ, Danielson GK, et al.; Task Force on Clinical Expert Consensus Documents. American College of Cardiology; Committee for Practice Guidelines. European Society of Cardiology. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2003;42(9):1687-713. doi:10.1016/s0735-1097(03)00941-0.

157

Barrett MJ, Ayub B, Martinez MW. Cardiac auscultation in sports medicine: strategies to improve clinical care. Curr Sports Med Rep. 2012;11(2):78-84. doi:10.1249/JSR.0b013e318249c0ff.

158

Cantwell JD. Preparticipation physical evaluation: getting to the heart of the matter. Med Sci Sports Exerc. 1998;30(10 Suppl):S341-4. doi:10.1097/00005768-199810001-00001.

159

Efthimiadis GK, Parcharidou D, Pagourelias ED, et al. Prevalence and clinical outcomes of incidentally diagnosed hypertrophic cardiomyopathy. Am J Cardiol. 2010;105(10):1445-50. doi:10.1016/j.amjcard.2009.12.066.

160

Harmon KG, Zigman M, Drezner JA. The effectiveness of screening history, physical exam, and ECG to detect potentially lethal cardiac disorders in athletes: a systematic review/meta-analysis. J Electrocardiol. 2015;48(3):329-38. doi:10.1016/j.jelectrocard.2015.02.001.

161

Raviele A, Giada F, Bergfeldt L, et al.; European Heart Rhythm Association. Management of patients with palpitations: a position paper from the European Heart Rhythm Association. Europace. 2011;13(7):920-34. doi:10.1093/europace/eur130.

162

Attenhofer Jost CH, Turina J, Mayer K, et al. Echocardiography in the evaluation of systolic murmurs of unknown cause. Am J Med. 2000;108(8):614-20. doi:10.1016/s0002-9343(00)00361-2.

163

Rapezzi C, Arbustini E, Caforio AL, et al. Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(19):1448-58. doi:10.1093/eurheartj/ehs397.

164

Rapezzi C, Quarta CC, Obici L, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J. 2013;34(7):520-8. doi:10.1093/eurheartj/ehs123.

165

Sarkozy A, Digilio MC, Dallapiccola B. Leopard syndrome. Orphanet J Rare Dis. 2008;3:13. doi:10.1186/1750-1172-3-13.

166

Scaglia F, Towbin JA, Craigen WJ, et al. Clinical spectrum, morbidity, and mortality in 113 pediatric patients with mitochondrial disease. Pediatrics. 2004;114(4):925-31. doi:10.1542/peds.2004-0718.

167

Pagourelias ED, Efthimiadis GK, Kouidi E, et al. Efficacy of various "classic" echocardiographic and laboratory indices in distinguishing the "gray zone" between athlete's heart and hypertrophic cardiomyopathy: a pilot study. Echocardiography. 2013;30(2):131-9. doi:10.1111/echo.12014.

168

Coutu M, Perrault LP, White M, et al. Cardiac transplantation for hypertrophic cardiomyopathy: a valid therapeutic option. J Heart Lung Transplant. 2004;23(4):413-7. doi:10.1016/S1053-2498(03)00225-0.

169

Zhang C, Huang X, Li J. Light chain amyloidosis: Where are the light chains from and how they play their pathogenic role? Blood Rev. 2017;31(4):261-70. doi:10.1016/j.blre.2017.03.002.

170

Ingles J, Burns C, Bagnall RD, et al. Nonfamilial Hypertrophic Cardiomyopathy: Prevalence, Natural History, and Clinical Implications. Circ Cardiovasc Genet. 2017;10(2):e001620. doi:10.1161/CIRCGENETICS.116.001620.

171

Maron BJ, Pelliccia A, Spirito P. Cardiac disease in young trained athletes. Insights into methods for distinguishing athlete's heart from structural heart disease, with particular emphasis on hypertrophic cardiomyopathy. Circulation. 1995;91(5):1596-601. doi:10.1161/01.cir.91.5.1596.

172

Young L, Smedira NG, Tower-Rader A, et al. Hypertrophic cardiomyopathy: A complex disease. Cleve Clin J Med. 2018;85(5):399-411. doi:10.3949/ccjm.85a.17076.

173

Efthimiadis GK, Pagourelias ED, Gossios T, Zegkos T. Hypertrophic cardiomyopathy in 2013: Current speculations and future perspectives. World J Cardiol. 2014;6(2):26-37. doi:10.4330/wjc.v6.i2.26.

174

Hershberger RE, Givertz MM, Ho CY, et al. Genetic Evaluation of Cardiomyopathy – A Heart Failure Society of America Practice Guideline. J Card Fail. 2018;24(5):281-302. doi:10.1016/j.cardfail.2018.03.004.

175

Efthimiadis GK, Pagourelias E, Zegkos T, et al. An Overview of Pharmacotherapy in Hypertrophic Cardiomyopathy: Current Speculations and Clinical Perspectives. Rev Cardiovasc Med. 2016;17(3-4):115-23.

176

Fananapazir L, Tracy CM, Leon MB, et al. Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy. A consecutive analysis in 155 patients. Circulation. 1989;80(5):1259-68. doi:10.1161/01.cir.80.5.1259.

177

Kelly BS, Mattu A, Brady WJ. Hypertrophic cardiomyopathy: electrocardiographic manifestations and other important considerations for the emergency physician. Am J Emerg Med. 2007;25(1):72-9. doi:10.1016/j.ajem.2006.04.017.

178

McLeod CJ, Ackerman MJ, Nishimura RA, et al. Outcome of patients with hypertrophic cardiomyopathy and a normal electrocardiogram. J Am Coll Cardiol. 2009;54(3):229-33. doi:10.1016/j.jacc.2009.02.071.

179

Wilke I, Witzel K, Münch J, et al. High Incidence of De Novo and Subclinical Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy and Cardiac Rhythm Management Device. J Cardiovasc Electrophysiol. 2016;27(7):779-84. doi:10.1111/jce.12982.

180

Хирманов В. Н., Трешкур Е. В., Тюрина Т. В. и др. Электрокардиографические методы в диагностике, выборе метода и тактики лечения гипертрофической кардиомиопатии. Progress in Biomedical Research: Сборник статей. СПб, 1997. Т. 2 (1), сс. 7-21.

Khirmanov VN, Treshkur EV, Tyurina TV, et al. Electrocardiographic methods in the diagnosis, choice of method and tactics of treatment of hypertrophic cardiomyopathy. Progress in Biomedical Research: A collection of articles. St. Petersburg, 1997. Vol. 2 (1), pp. 7-21.

181

O'Mahony C, Jichi F, Pavlou M, et al.; Hypertrophic Cardiomyopathy Outcomes Investigators. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J. 2014;35(30):2010-20. doi:10.1093/eurheartj/eht439.

182

Wasfy MM, Weiner RB. Differentiating the athlete's heart from hypertrophic cardiomyopathy. Curr Opin Cardiol. 2015;30(5):500-5. doi:10.1097/HCO.0000000000000203.

183

Weigner MJ, Caulfield TA, Danias PG, et al. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med. 1997;126(8):615-20. doi:10.7326/0003-4819-126-8-199704150-00005.

184

Guttmann OP, Rahman MS, O'Mahony C, et al. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. Heart. 2014;100(6):465-72. doi:10.1136/heartjnl-2013-304276.

185

Task Force members, Brignole M, Vardas P, Hoffman E, et al.; EHRA Scientific Documents Committee. Indications for the use of diagnostic implantable and external ECG loop recorders. Europace. 2009;11(5):671-87. doi:10.1093/europace/eup097. Erratum in: Europace. 2009;11(6):836.

186

Frangini PA, Cecchin F, Jordao L, et al. How revealing are insertable loop recorders in pediatrics? Pacing Clin Electrophysiol. 2008;31(3):338-43. doi:10.1111/j.1540-8159.2008.00995.x.

187

Solano A, Menozzi C, Maggi R, et al. Incidence, diagnostic yield and safety of the implantable loop-recorder to detect the mechanism of syncope in patients with and without structural heart disease. Eur Heart J. 2004;25(13):1116-9. doi:10.1016/j.ehj.2004.05.013.

188

Moon JC, Reed E, Sheppard MN, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;43(12):2260-4. doi:10.1016/j.jacc.2004.03.035.

189

O'Hanlon R, Grasso A, Roughton M, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56(11):867-74. doi:10.1016/j.jacc.2010.05.010.

190

Pernat A, Pohar B, Horvat M. Heart conduction disturbances and cardiovascular collapse after disopyramide and low-dose metoprolol in a patient with hypertrophic obstructive cardiomyopathy. J Electrocardiol. 1997;30(4):341-4. doi:10.1016/s0022-0736(97)80048-9.

191

Cerqueira MD, Weissman NJ, Dilsizian V, et al.; American Heart Association Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002;105(4):539-42. doi:10.1161/hc0402.102975.

192

Flachskampf FA, Badano L, Daniel WG, et al. Recommendations for transoesophageal echocardiography: update 2010. Eur J Echocardiogr. 2010;11(7):557-76. doi:10.1093/ejechocard/jeq057. Erratum in: Eur J Echocardiogr. 2011;12(3):255.

193

Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16(3):233-70. doi:10.1093/ehjci/jev014. Erratum in: Eur Heart J Cardiovasc Imaging. 2016;17(4):412. Erratum in: Eur Heart J Cardiovasc Imaging. 2016;17(9):969.

194

Mitchell C, Rahko PS, Blauwet LA, et al. Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr. 2019;32(1):1-64. doi:10.1016/j.echo.2018.06.004.

195

Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr. 2009;10(2):165-93. doi:10.1093/ejechocard/jep007.

196

Senior R, Becher H, Monaghan M, et al. Contrast echocardiography: evidence-based recommendations by European Association of Echocardiography. Eur J Echocardiogr. 2009;10(2):194-212. doi:10.1093/ejechocard/jep005.

197

Maron BJ, Casey SA, Hauser RG, Aeppli DM. Clinical course of hypertrophic cardiomyopathy with survival to advanced age. J Am Coll Cardiol. 2003;42(5):882-8. doi:10.1016/s0735-1097(03)00855-6.

198

Maron BJ, Rowin EJ, Maron MS, Braunwald E. Nonobstructive Hypertrophic Cardiomyopathy Out of the Shadows: Known from the Beginning but Largely Ignored … Until Now. Am J Med. 2017;130(2):119-23. doi:10.1016/j.amjmed.2016.09.015.

199

Maron MS, Olivotto I, Zenovich AG, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006;114(21):2232-9. doi:10.1161/CIRCULATIONAHA.106.644682.

200

Spirito P, Autore C, Formisano F, et al. Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors. Am J Cardiol. 2014;113(9):1550-5. doi:10.1016/j.amjcard.2014.01.435.

201

Spirito P, Bellone P, Harris KM, et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000;342(24):1778-85. doi:10.1056/NEJM200006153422403.

202

Belenkie I, MacDonald RP, Smith ER. Localized septal hypertrophy: part of the spectrum of hypertrophic cardiomyopathy or an incidental echocardiographic finding? Am Heart J. 1988;115(2):385-90. doi:10.1016/0002-8703(88)90486-3.

203

Gardin J, Palabrica T, Dubria S, et al. Localized basal ventricular septal hypertrophy - prevalence, functional and clinical correlates in a population referred for echocardiography. Am J Noninvas Card. 1992;6(1):5-8. doi:10.1159/000470319.

204

Losi MA, Nistri S, Galderisi M, et al.; Working Group of Echocardiography of the Italian Society of Cardiology. Echocardiography in patients with hypertrophic cardiomyopathy: usefulness of old and new techniques in the diagnosis and pathophysiological assessment. Cardiovasc Ultrasound. 2010;8:7. doi:10.1186/1476-7120-8-7.

205

Alvares RF, Goodwin JF. Non-invasive assessment of diastolic function in hypertrophic cardiomyopathy on and off beta adrenergic blocking drugs. Br Heart J. 1982;48(3):204-12. doi:10.1136/hrt.48.3.204.

206

Dimitrow PP, Bober M, Michałowska J, Sorysz D. Left ventricular outflow tract gradient provoked by upright position or exercise in treated patients with hypertrophic cardiomyopathy without obstruction at rest. Echocardiography. 2009;26(5):513-20. doi:10.1111/j.1540-8175.2008.00851.x.

207

Elliott P, Gimeno J, Tomé M, McKenna W. Left ventricular outflow tract obstruction and sudden death in hypertrophic cardiomyopathy. Eur Heart J. 2006;27(24):3073; author reply 3073-4. doi:10.1093/eurheartj/ehl383.

208

Nistri S, Olivotto I, Maron MS, et al. Timing and significance of exercise-induced left ventricular outflow tract pressure gradients in hypertrophic cardiomyopathy. Am J Cardiol. 2010;106(9):1301-6. doi:10.1016/j.amjcard.2010.06.057.

209

Olivotto I, Montereggi A, Mazzuoli F, Cecchi F. Clinical utility and safety of exercise testing in patients with hypertrophic cardiomyopathy. G Ital Cardiol. 1999;29(1):11-9.

210

Sadoul N, Prasad K, Elliott PM, et al. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation. 1997;96(9):2987-91. doi:10.1161/01.cir.96.9.2987.

211

Tower-Rader A, Betancor J, Lever HM, Desai MY. A Comprehensive Review of Stress Testing in Hypertrophic Cardiomyopathy: Assessment of Functional Capacity, Identification of Prognostic Indicators, and Detection of Coronary Artery Disease. J Am Soc Echocardiogr. 2017;30(9):829-44. doi:10.1016/j.echo.2017.05.017.

212

Yalçin F, Muderrisoglu H, Korkmaz ME, et al. The effect of dobutamine stress on left ventricular outflow tract gradients in hypertensive patients with basal septal hypertrophy. Angiology. 2004;55(3):295-301. doi:10.1177/000331970405500309.

213

Mestres CA, Bartel T, Sorgente A, et al. Hypertrophic obstructive cardiomyopathy: what, when, why, for whom? Eur J Cardiothorac Surg. 2018;53(4):700-7. doi:10.1093/ejcts/ezy020.

214

Mickelsen S, Bathina M, Hsu P, et al. Doppler evaluation of the descending aorta in patients with hypertrophic cardiomyopathy: potential for assessing the functional significance of outflow tract gradients and for optimizing pacemaker function. J Interv Card Electrophysiol. 2004;11(1):47-53. doi:10.1023/B:JICE.0000035929.84238.2f.

215

Tezuka A, Higo K, Nakamukae Y, et al. Bisoprolol Successfully Improved the Intraventricular Pressure Gradient in a Patient with Midventricular Obstructive Hypertrophic Cardiomyopathy with an Apex Aneurysm due to Apical Myocardial Damage. Intern Med. 2019;58(4):535-9. doi:10.2169/internalmedicine.0997-18.

216

Cardim N, Galderisi M, Edvardsen T, et al. Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: an expert consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association. Eur Heart J Cardiovasc Imaging. 2015;16(3):280. doi:10.1093/ehjci/jeu291.

217

Kim MS, Klein AJ, Groves BM, et al. Left ventricular outflow tract obstruction in the presence of asymmetric septal hypertrophy and accessory mitral valve tissue treated with alcohol septal ablation. Eur J Echocardiogr. 2008;9(5):720-4. doi:10.1093/ejechocard/jen152.

218

Monakier D, Woo A, Puri T, et al. Usefulness of myocardial contrast echocardiographic quantification of risk area for predicting postprocedural complications in patients undergoing septal ethanol ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2004;94(12):1515-22. doi:10.1016/j.amjcard.2004.08.030.

219

Wallace EL, Thompson JJ, Faulkner MW, et al. Septal perforator anatomy and variability of perfusion bed by myocardial contrast echocardiography: a study of hypertrophic cardiomyopathy patients undergoing alcohol septal ablation. J Interv Cardiol. 2013;26(6):604-12. doi:10.1111/joic.12068.

220

Grigg LE, Wigle ED, Williams WG, et al. Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: clarification of pathophysiology and importance in intraoperative decision making. J Am Coll Cardiol. 1992;20(1):42-52. doi:10.1016/0735-1097(92)90135-a.

221

Marwick TH, Stewart WJ, Lever HM, et al. Benefits of intraoperative echocardiography in the surgical management of hypertrophic cardiomyopathy. J Am Coll Cardiol. 1992;20(5):1066-72. doi:10.1016/0735-1097(92)90359-u.

222

Oki T, Fukuda N, Iuchi A, et al. Transesophageal echocardiographic evaluation of mitral regurgitation in hypertrophic cardiomyopathy: contributions of eccentric left ventricular hypertrophy and related abnormalities of the mitral complex. J Am Soc Echocardiogr. 1995;8(4):503-10. doi:10.1016/s0894-7317(05)80338-4.

223

Yu EH, Omran AS, Wigle ED, et al. Mitral regurgitation in hypertrophic obstructive cardiomyopathy: relationship to obstruction and relief with myectomy. J Am Coll Cardiol. 2000;36(7):2219-25. doi:10.1016/s0735-1097(00)01019-6.

224

McIntosh CL, Maron BJ, Cannon RO 3rd, Klues HG. Initial results of combined anterior mitral leaflet plication and ventricular septal myotomy-myectomy for relief of left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. Circulation. 1992;86(5 Suppl):II60-7.

225

Green JJ, Berger JS, Kramer CM, Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc Imaging. 2012;5(4):370-7. doi:10.1016/j.jcmg.2011.11.021.

226

Moon JC, Fisher NG, McKenna WJ, Pennell DJ. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart. 2004;90(6):645-9. doi:10.1136/hrt.2003.014969.

227

Olivotto I, Maron MS, Autore C, et al. Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2008;52(7):559-66. doi:10.1016/j.jacc.2008.04.047.

228

Prinz C, Schwarz M, Ilic I, et al. Myocardial fibrosis severity on cardiac magnetic resonance imaging predicts sustained arrhythmic events in hypertrophic cardiomyopathy. Can J Cardiol. 2013;29(3):358-63. doi:10.1016/j.cjca.2012.05.004.

229

Rickers C, Wilke NM, Jerosch-Herold M, et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation. 2005;112(6):855-61. doi:10.1161/CIRCULATIONAHA.104.507723.

230

Rudolph A, Abdel-Aty H, Bohl S, et al. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. J Am Coll Cardiol. 2009;53(3):284-91. doi:10.1016/j.jacc.2008.08.064.

231

Webb J, Fovargue L, Tøndel K, et al. The Emerging Role of Cardiac Magnetic Resonance Imaging in the Evaluation of Patients with HFpEF. Curr Heart Fail Rep. 2018;15(1):1-9. doi:10.1007/s11897-018-0372-1.

232

Albano BB, Fadreguilan EC, Chua JM, et al. Treating a Structural Heart Disease Using a Non-structural Approach: Role of Cardiac Pacing in Hypertrophic Cardiomyopathy. Cardiol Res. 2017;8(1):20-5. doi:10.14740/cr512w.

233

Puntmann VO, Gebker R, Duckett S, et al. Left ventricular chamber dimensions and wall thickness by cardiovascular magnetic resonance: comparison with transthoracic echocardiography. Eur Heart J Cardiovasc Imaging. 2013;14(3):240-6. doi:10.1093/ehjci/jes145.

234

Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;112(13):2047-60. doi:10.1161/CIRCULATIONAHA.104.489187.

235

Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016;133(24):2404-12. doi:10.1161/CIRCULATIONAHA.116.021612.

236

Syed IS, Glockner JF, Feng D, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging. 2010;3(2):155-64. doi:10.1016/j.jcmg.2009.09.023.

237

Todiere G, Aquaro GD, Piaggi P, et al. Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2012;60(10):922-9. doi:10.1016/j.jacc.2012.03.076.

238

O'Hanlon R, Assomull RG, Prasad SK. Use of cardiovascular magnetic resonance for diagnosis and management in hypertrophic cardiomyopathy. Curr Cardiol Rep. 2007;9(1):51-6. doi:10.1007/s11886-007-0010-0.

239

Patel P, Dhillon A, Popovic ZB, et al. Left Ventricular Outflow Tract Obstruction in Hypertrophic Cardiomyopathy Patients Without Severe Septal Hypertrophy: Implications of Mitral Valve and Papillary Muscle Abnormalities Assessed Using Cardiac Magnetic Resonance and Echocardiography. Circ Cardiovasc Imaging. 2015;8(7):e003132. doi:10.1161/CIRCIMAGING.115.003132.

240

Gruner C, Chan RH, Crean A, et al. Significance of left ventricular apical-basal muscle bundle identified by cardiovascular magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Eur Heart J. 2014;35(39):2706-13. doi:10.1093/eurheartj/ehu154.

241

Brouwer WP, Germans T, Head MC, et al. Multiple myocardial crypts on modified long-axis view are a specific finding in pre-hypertrophic HCM mutation carriers. Eur Heart J Cardiovasc Imaging. 2012;13(4):292-7. doi:10.1093/ehjci/jes005.

242

Schroeder S, Achenbach S, Bengel F, et al.; Working Group Nuclear Cardiology and Cardiac CT; European Society of Cardiology; European Council of Nuclear Cardiology. Cardiac computed tomography: indications, applications, limitations, and training requirements: report of a Writing Group deployed by the Working Group Nuclear Cardiology and Cardiac CT of the European Society of Cardiology and the European Council of Nuclear Cardiology. Eur Heart J. 2008;29(4):531-56. doi:10.1093/eurheartj/ehm544.

243

Esposito A, Colantoni C, De Cobelli F, et al. Multidetector computed tomography for coronary stents imaging: high-voltage (140-kVp) prospective ECG-triggered versus standard-voltage (120-kVp) retrospective ECG-gated helical scanning. J Comput Assist Tomogr. 2013;37(3):395-401. doi:10.1097/RCT.0b013e3182873559.

244

Shiozaki AA, Senra T, Arteaga E, et al. Myocardial fibrosis detected by cardiac CT predicts ventricular fibrillation/ventricular tachycardia events in patients with hypertrophic cardiomyopathy. J Cardiovasc Comput Tomogr. 2013;7(3):173-81. doi:10.1016/j.jcct.2013.04.002.

245

Rapezzi C, Quarta CC, Guidalotti PL, et al. Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging. 2011;38(3):470-8. doi:10.1007/s00259-010-1642-7.

246

Rapezzi C, Quarta CC, Guidalotti PL, et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging. 2011;4(6):659-70. doi:10.1016/j.jcmg.2011.03.016.

247

Katayama M, Panse PM, Kendall CB, et al. Left Ventricular Septal Hypertrophy in Elderly Patients With Aortic Stenosis. J Ultrasound Med. 2018;37(1):217-24. doi:10.1002/jum.14320.

248

Mitsutake R, Miura S, Sako H, et al. Usefulness of multi-detector row computed tomography for the management of percutaneous transluminal septal myocardial ablation in patient with hypertrophic obstructive cardiomyopathy. Int J Cardiol. 2008;129(2):e61-3. doi:10.1016/j.ijcard.2007.06.132.

249

Scalone G, Niccoli G, Crea F. Editor's Choice – Pathophysiology, diagnosis and management of MINOCA: an update. Eur Heart J Acute Cardiovasc Care. 2019;8(1):54-62. doi:10.1177/2048872618782414.

250

Okayama S, Uemura S, Soeda T, et al. Role of cardiac computed tomography in planning and evaluating percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy. J Cardiovasc Comput Tomogr. 2010;4(1):62-5. doi:10.1016/j.jcct.2009.10.004.

251

Villa AD, Sammut E, Zarinabad N, et al. Microvascular ischemia in hypertrophic cardiomyopathy: new insights from high-resolution combined quantification of perfusion and late gadolinium enhancement. J Cardiovasc Magn Reson. 2016;18:4. doi:10.1186/s12968-016-0223-8.

252

Chen JM, Levin HR, Michler RE, et al. Reevaluating the significance of pulmonary hypertension before cardiac transplantation: determination of optimal thresholds and quantification of the effect of reversibility on perioperative mortality. J Thorac Cardiovasc Surg. 1997;114(4):627-34. doi:10.1016/S0022-5223(97)70053-9.

253

Kato TS, Takayama H, Yoshizawa S, et al. Cardiac transplantation in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2012;110(4):568-74. doi:10.1016/j.amjcard.2012.04.030.

254

Lindelöw B, Andersson B, Waagstein F, Bergh CH. High and low pulmonary vascular resistance in heart transplant candidates. A 5-year follow-up after heart transplantation shows continuous reduction in resistance and no difference in complication rate. Eur Heart J. 1999;20(2):148-56. doi:10.1053/euhj.1998.1155.

255

Maron MS, Kalsmith BM, Udelson JE, et al. Survival after cardiac transplantation in patients with hypertrophic cardiomyopathy. Circ Heart Fail. 2010;3(5):574-9. doi:10.1161/CIRCHEARTFAILURE.109.922872.

256

Mehra MR, Kobashigawa J, Starling R, et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates – 2006. J Heart Lung Transplant. 2006;25(9):1024-42. doi:10.1016/j.healun.2006.06.008.

257

Torres MF, Perez-Villa F. Heart transplantation in patients with hypertrophic cardiomyopathy. Glob Cardiol Sci Pract. 2018;2018(3):32. doi:10.21542/gcsp.2018.32.

258

Blomström-Lundqvist C, Scheinman MM, Aliot EM, et al.; European Society of Cardiology Committee, NASPE-Heart Rhythm Society. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias – executive summary: a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society. J Am Coll Cardiol. 2003;42(8):1493-531. doi:10.1016/j.jacc.2003.08.013.

259

Бокерия Л. А., Берсенёва М. И., Маленков Д. А. Аритмогенные осложнения гипертрофической кардиомиопатии. Анналы аритмологии. 2010;7(3):62-9.

Bockeria LA, Bersenyova MI, Malenkov DA. Arrhythmogenic complications of hypertrophic cardiomyopathy. Annals of Arrhythmology. 2010;7(3):62-9.

260

Muresan L, Cismaru G, Martins RP, et al. Recommendations for the use of electrophysiological study: Update 2018. Hellenic J Cardiol. 2019;60(2):82-100. doi:10.1016/j.hjc.2018.09.002.

261

Wang W, Lian Z, Rowin EJ, et al. Prognostic Implications of Nonsustained Ventricular Tachycardia in High-Risk Patients With Hypertrophic Cardiomyopathy. Circ Arrhythm Electrophysiol. 2017;10(3):e004604. doi:10.1161/CIRCEP.116.004604.

262

Inada K, Seiler J, Roberts-Thomson KC, et al. Substrate characterization and catheter ablation for monomorphic ventricular tachycardia in patients with apical hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2011;22(1):41-8. doi:10.1111/j.1540-8167.2010.01875.x.

263

Lim KK, Maron BJ, Knight BP. Successful catheter ablation of hemodynamically unstable monomorphic ventricular tachycardia in a patient with hypertrophic cardiomyopathy and apical aneurysm. J Cardiovasc Electrophysiol. 2009;20(4):445-7. doi:10.1111/j.1540-8167.2008.01366.x.

264

Refaat MM, Hotait M, Tseng ZH. Utility of the exercise electrocardiogram testing in sudden cardiac death risk stratification. Ann Noninvasive Electrocardiol. 2014;19(4):311-8. doi:10.1111/anec.12191.

265

Yi G, Poloniecki J, Dickie S, et al. Can the assessment of dynamic QT dispersion on exercise electrocardiogram predict sudden cardiac death in hypertrophic cardiomyopathy? Pacing Clin Electrophysiol. 2000;23(11 Pt 2):1953-6. doi:10.1111/j.1540-8159.2000.tb07060.x.

266

Nistri S, Olivotto I, Maron MS, et al. β Blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2012;110(5):715-9. doi:10.1016/j.amjcard.2012.04.051.

267

Rowin EJ, Maron BJ, Olivotto I, Maron MS. Role of Exercise Testing in Hypertrophic Cardiomyopathy. JACC Cardiovasc Imaging. 2017;10(11):1374-86. doi:10.1016/j.jcmg.2017.07.016.

268

Mancini DM, Eisen H, Kussmaul W, et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation. 1991;83(3):778-86. doi:10.1161/01.cir.83.3.778.

269

Sharma S, Elliott P, Whyte G, et al. Utility of cardiopulmonary exercise in the assessment of clinical determinants of functional capacity in hypertrophic cardiomyopathy. Am J Cardiol. 2000;86(2):162-8. doi:10.1016/s0002-9149(00)00854-7.

270

Колоскова Н. Н., Шаталов К. В., Бокерия Л. А. Определение пикового потребления кислорода: клиническое использование и перспективы. Креативная кардиология. 2014;(2):20-8.

Koloskova NN, Shatalov KV, Bokeria LA. Determination of peak oxygen consumption: clinical use and prospects. Creative cardiology. 2014;(2):20-8.

271

Coats CJ, Rantell K, Bartnik A, et al. Cardiopulmonary Exercise Testing and Prognosis in Hypertrophic Cardiomyopathy. Circ Heart Fail. 2015;8(6):1022-31. doi:10.1161/CIRCHEARTFAILURE.114.002248.

272

Arena R, Owens DS, Arevalo J, et al. Ventilatory efficiency and resting hemodynamics in hypertrophic cardiomyopathy. Med Sci Sports Exerc. 2008;40(5):799-805. doi:10.1249/MSS.0b013e31816459a1.

273

Olivotto I, Maron BJ, Montereggi A, et al. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1999;33(7):2044-51. doi:10.1016/s0735-1097(99)00094-7.

274

Diodati JG, Schenke WH, Waclawiw MA, et al. Predictors of exercise benefit after operative relief of left ventricular outflow obstruction by the myotomy-myectomy procedure in hypertrophic cardiomyopathy. Am J Cardiol. 1992;69(19):1617-22. doi:10.1016/0002-9149(92)90713-9.

275

Bennett MK, Gilotra NA, Harrington C, et al. Evaluation of the role of endomyocardial biopsy in 851 patients with unexplained heart failure from 2000-2009. Circ Heart Fail. 2013;6(4):676-84. doi:10.1161/CIRCHEARTFAILURE.112.000087.

276

Schönland SO, Hegenbart U, Bochtler T, et al. Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood. 2012;119(2):488-93. doi:10.1182/blood-2011-06-358507.

277

Quarta CC, Gonzalez-Lopez E, Gilbertson JA, et al. Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. Eur Heart J. 2017;38(24):1905-8. doi:10.1093/eurheartj/ehx047.

278

Крылова Н. С., Хашиева Ф. М., Демкина А. Е. и др. Гипертрофическая кардиомиопатия и артериальная гипертензия: возможно ли сочетание? Сердце: журнал для практикующих врачей. 2015;14(3):164-9.

Krylova NS, Khashieva FM, Demkina AE, et al. Hypertrophic cardiomyopathy and arterial hypertension: is a combination possible? Heart: magazine for practicing physicians. 2015;14(3):164-9.

279

Полякова А. А., Гудкова А. Я., Крутиков А. Н. и др. Гипертрофическая кардиомиопатия в старшей возрастной группе: влияние факторов кардиометаболического риска и полиморфизма гена MADD. Артериальная гипертензия. 2018;24(1):29-40. doi:10.18705/1607-419X-2018-24-1-29-40.

Poliakova AA, Gudkova AYu, Krutikov AN, et al. Hypertrophic cardiomyopathy in the older age group: the effect of cardiometabolic risk factors and RS2290149 and RS10838692 of the madd gene. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2018;24(1):29-40. doi:10.18705/1607-419X-2018-24-1-29-40.

280

Abel ED, Litwin SE, Sweeney G. Cardiac remodeling in obesity. Physiol Rev. 2008;88(2):389-419. doi:10.1152/physrev.00017.2007.

281

Ommen SR, Lopez-Jimenez F. Obesity and hypertrophic cardiomyopathy: chickens, eggs, and causality: clinical skills remain the key to caring for patients. J Am Coll Cardiol. 2013;62(5):458-9. doi:10.1016/j.jacc.2013.03.063.

282

Olivotto I, Maron BJ, Tomberli B, et al. Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013;62(5):449-57. doi:10.1016/j.jacc.2013.03.062.

283

van Straten AH, Soliman Hamad MA, Peels KC, et al. Increased septum wall thickness in patients undergoing aortic valve replacement predicts worse late survival. Ann Thorac Surg. 2012;94(1):66-71. doi:10.1016/j.athoracsur.2012.03.027.

284

Di Tommaso L, Stassano P, Mannacio V, et al. Asymmetric septal hypertrophy in patients with severe aortic stenosis: the usefulness of associated septal myectomy. J Thorac Cardiovasc Surg. 2013;145(1):171-5. doi:10.1016/j.jtcvs.2011.10.096.

285

Dweck MR, Joshi S, Murigu T, et al. Left ventricular remodeling and hypertrophy in patients with aortic stenosis: insights from cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2012;14(1):50. doi:10.1186/1532-429X-14-50.

286

Maron BJ, Edwards JE, Epstein SE. Disproportionate ventricular thickening in patients with systemic hypertension. Chest. 1978;73(4):466-70. doi:10.1378/chest.73.4.466.

287

Rodrigues JC, Amadu AM, Dastidar AG, et al. Prevalence and predictors of asymmetric hypertensive heart disease: insights from cardiac and aortic function with cardiovascular magnetic resonance. Eur Heart J Cardiovasc Imaging. 2016;17(12):1405-13. doi:10.1093/ehjci/jev329.

288

Tuseth N, Cramariuc D, Rieck AE, et al. Asymmetric septal hypertrophy – marker of hypertension in aortic stenosis (a SEAS substudy). Blood Press. 2010;19(3):140-4. doi:10.3109/08037051.2010.481816.

289

Shapiro LM, Howat AP, Crean PA, Westgate CJ. An echocardiographic study of localized subaortic hypertrophy. Eur Heart J. 1986;7(2):127-32. doi:10.1093/oxfordjournals.eurheartj.a062034.

290

Raissuni Z, Doghmi N, Mousseaux E, et al. Hypertrophic cardiomyopathy mimicking STEMI: The role of cardiac magnetic resonance imaging in the detection of microvascular coronary dysfunction. Diagn Interv Imaging. 2014;95(11):1111-2. doi:10.1016/j.diii.2013.12.020.

291

Timmer SA, Knaapen P. Coronary microvascular function, myocardial metabolism, and energetics in hypertrophic cardiomyopathy: insights from positron emission tomography. Eur Heart J Cardiovasc Imaging. 2013;14(2):95-101. doi:10.1093/ehjci/jes242.

292

Zhang YD, Li M, Qi L, et al. Hypertrophic cardiomyopathy: Cardiac structural and microvascular abnormalities as evaluated with multi-parametric MRI. Eur J Radiol. 2015;84(8):1480-6. doi:10.1016/j.ejrad.2015.04.028.

293

Gutiérrez-Barrios A, Camacho-Jurado F, Díaz-Retamino E, et al. Invasive assessment of coronary microvascular dysfunction in hypertrophic cardiomyopathy: the index of microvascular resistance. Cardiovasc Revasc Med. 2015;16(7):426-8. doi:10.1016/j.carrev.2015.06.008.

294

Ismail TF, Hsu LY, Greve AM, et al. Coronary microvascular ischemia in hypertrophic cardiomyopathy - a pixel-wise quantitative cardiovascular magnetic resonance perfusion study. J Cardiovasc Magn Reson. 2014;16(1):49. doi:10.1186/s12968-014-0049-1.

295

Olivotto I, Girolami F, Sciagrà R, et al. Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations. J Am Coll Cardiol. 2011;58(8):839-48. doi:10.1016/j.jacc.2011.05.018.

296

Zipes DP, Camm AJ, Borggrefe M, et al.; American College of Cardiology/American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114(10):e385-484. doi:10.1161/CIRCULATIONAHA.106.178233.

297

Basavarajaiah S, Wilson M, Whyte G, et al. Prevalence of hypertrophic cardiomyopathy in highly trained athletes: relevance to pre-participation screening. J Am Coll Cardiol. 2008;51(10):1033-9. doi:10.1016/j.jacc.2007.10.055.

298

Malhotra A, Sharma S. Hypertrophic Cardiomyopathy in Athletes. Eur Cardiol. 2017;12(2):80-2. doi:10.15420/ecr.2017:12:1.

299

Pelliccia A, Solberg EE, Papadakis M, et al. Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC). Eur Heart J. 2019;40(1):19-33. doi:10.1093/eurheartj/ehy730.

300

Liebregts M, Faber L, Jensen MK, et al. Validation of the HCM Risk-SCD model in patients with hypertrophic cardiomyopathy following alcohol septal ablation. Europace. 2018;20(FI2):f198-f203. doi:10.1093/europace/eux251.

301

Spoladore R, Maron MS, D'Amato R, et al. Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence. Eur Heart J. 2012;33(14):1724-33. doi:10.1093/eurheartj/ehs150.

302

Toshima H, Koga Y, Nagata H, et al. Comparable effects of oral diltiazem and verapamil in the treatment of hypertrophic cardiomyopathy. Double-blind crossover study. Jpn Heart J. 1986;27(5):701-15. doi:10.1536/ihj.27.701.

303

Galve E, Sambola A, Saldaña G, et al. Late benefits of dual-chamber pacing in obstructive hypertrophic cardiomyopathy: a 10-year follow-up study. Heart. 2010;96(5):352-6. doi:10.1136/hrt.2008.158915.

304

Gentry JL 3rd, Mentz RJ, Hurdle M, Wang A. Ranolazine for Treatment of Angina or Dyspnea in Hypertrophic Cardiomyopathy Patients (RHYME). J Am Coll Cardiol. 2016;68(16):1815-7. doi:10.1016/j.jacc.2016.07.758.

305

Kappenberger L, Linde C, Daubert C, et al. Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study. PIC Study Group. Eur Heart J. 1997(8):1249-56. doi:10.1093/oxfordjournals.eurheartj.a015435.

306

Maron BJ, Nishimura RA, McKenna WJ, et al. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation. 1999;99(22):2927-33. doi:10.1161/01.cir.99.22.2927.

307

Maron MS, Chan RH, Kapur NK, et al. Effect of Spironolactone on Myocardial Fibrosis and Other Clinical Variables in Patients with Hypertrophic Cardiomyopathy. Am J Med. 2018;131(7):837-41. doi:10.1016/j.amjmed.2018.02.025.

308

Nishimura RA, Trusty JM, Hayes DL, et al. Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. J Am Coll Cardiol. 1997;29(2):435-41. doi:10.1016/s0735-1097(96)00473-1.

309

Olivotto I, Camici PG, Merlini PA, et al. Efficacy of Ranolazine in Patients With Symptomatic Hypertrophic Cardiomyopathy: The RESTYLE-HCM Randomized, Double-Blind, Placebo-Controlled Study. Circ Heart Fail. 2018;11(1):e004124. doi:10.1161/CIRCHEARTFAILURE.117.004124.

310

Slade AK, Sadoul N, Shapiro L, et al. DDD pacing in hypertrophic cardiomyopathy: a multicentre clinical experience. Heart. 1996;75(1):44-9. doi:10.1136/hrt.75.1.44.

311

Jung H, Yang PS, Jang E, et al. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation With Hypertrophic Cardiomyopathy: A Nationwide Cohort Study. Chest. 2019;155(2):354-63. doi:10.1016/j.chest.2018.11.009.

312

Zhou Y, He W, Zhou Y, Zhu W. Non-vitamin K antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation: a systematic review and meta-analysis. J Thromb Thrombolysis. 2020;50(2):311-7. doi:10.1007/s11239-019-02008-3.

313

Rujirachun P, Charoenngam N, Wattanachayakul P, et al. Efficacy and safety of direct oral anticoagulants (DOACs) versus vitamin K antagonist (VKA) among patients with atrial fibrillation and hypertrophic cardiomyopathy: a systematic review and meta-analysis. Acta Cardiol. 2020;75(8):724-31. doi:10.1080/00015385.2019.1668113.

314

Patten M, Pecha S, Aydin A. Atrial Fibrillation in Hypertrophic Cardiomyopathy: Diagnosis and Considerations for Management. J Atr Fibrillation. 2018;10(5):1556. doi:10.4022/jafib.1556.

315

Dearani JA, Ommen SR, Gersh BJ, et al. Surgery insight: Septal myectomy for obstructive hypertrophic cardiomyopathy–the Mayo Clinic experience. Nat Clin Pract Cardiovasc Med. 2007;4(9):503-12. doi:10.1038/ncpcardio0965.

316

Leonardi RA, Kransdorf EP, Simel DL, Wang A. Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy: comparative rates of overall mortality and sudden cardiac death after treatment. Circ Cardiovasc Interv. 2010;3(2):97-104. doi:10.1161/CIRCINTERVENTIONS.109.916676.

317

Zeng Z, Wang F, Dou X, et al. Comparison of percutaneous transluminal septal myocardial ablation versus septal myectomy for the treatment of patients with hypertrophic obstructive cardiomyopathy – a meta analysis. Int J Cardiol. 2006;112(1):80-4. doi:10.1016/j.ijcard.2005.10.009.

318

Afanasyev AV, Bogachev-Prokophiev AV, Ovcharov MA, et al. Single-Centre Experience of Surgical Myectomy for Hypertrophic Obstructive Cardiomyopathy. Heart Lung Circ. 2020;29(6):949-55. doi:10.1016/j.hlc.2019.07.009.

319

Veselka J, Faber L, Liebregts M, et al. Short- and long-term outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy in patients with mild left ventricular hypertrophy: a propensity score matching analysis. Eur Heart J. 2019;40(21):1681-7. doi:10.1093/eurheartj/ehz110.

320

Майстренко А. Д., Гурщенков А. В., Паскарь Н. С. и др. Современное состояние проблемы хирургического лечения гипертрофической обструктивной кардиомиопатии. Вестник хирургии имени И.И. Грекова. 2013;172(2):082-7. doi:10.24884/0042-4625-2013-172-2-082-087.

Maistrenko AD, Gurschenkov AV, Paskar NS, et al. Current state of the problem of surgical treatment of hypertrophic obstructive cardiomyopathy. I. I. Grekov Bulletin of Surgery. 2013;172(2):082-087. doi:10.24884/0042-4625-2013-172-2-082-087.

321

Хитрова М. Э., Бокерия Л. А., Берсенева М. И. и др. Метаанализ результатов хирургического лечения гипертрофической обструктивной кардиомиопатии. Креативная кардиология. 2017;11(4):337-47. doi:10.24022/1997-3187-2017-11-4-337-347.

Khitrova ME, Bockeria LA, Berseneva MI, et al. Meta-analysis of results the surgical treatment hypertrophic obstructive cardiomyopathy. Kreativnaya Kardiologiya (Creative Cardiology). 2017;11(4):337-47 doi:10.24022/1997-3187-2017-11-4-337-347.

322

Богданов Д. В., Шапошник И. И. Варианты клинического течения, исходы и прогноз гипертрофической необструктивной кардиомиопатии – результаты длительного наблюдения. Российский кардиологический журнал. 2019;(11):48-54. doi:10.15829/1560-4071-2019-11-48-54.

Bogdanov DV, Shaposhnik II. Clinical variants, outcomes and prognosis of hypertrophic non-obstructive cardiomyopathy: results of long-term follow-up. Russian Journal of Cardiology. 2019;(11):48-54. doi:10.15829/1560-4071-2019-11-48-54.

323

Vriesendorp PA, Schinkel AF, Liebregts M, et al. Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol. 2015;8(4):829-35. doi:10.1161/CIRCEP.114.002553.

324

Falk V, Baumgartner H, Bax JJ, et al.; ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur J Cardiothorac Surg. 2017;52(4):616-64. doi:10.1093/ejcts/ezx324. Erratum in: Eur J Cardiothorac Surg. 2017;52(4):832.

325

Lourenço AP, Leite-Moreira AF, Balligand JL, et al. An integrative translational approach to study heart failure with preserved ejection fraction: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology. Eur J Heart Fail. 2018;20(2):216-27. doi:10.1002/ejhf.1059.

326

Мареев В. Ю., Фомин И. В., Агеев Ф. Т. и др. Клинические рекомендации ОССН - РКО - РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). диагностика, профилактика и лечение. Кардиология. 2018;58(6S):8-158. doi:10.18087/cardio.2475.

Mareev VYu, Fomin IV, Ageev FT, et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(6S):8-158. doi:10.18087/cardio.2475.

327

Кобалава Ж. Д., Конради А. О., Недогода С. В. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):3786. doi:10.15829/1560-4071-2020-3-3786.

Kobalava ZD, Konradi AO, Nedogoda SV, et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. doi:10.15829/1560-4071-2020-3-3786.

328

Гудкова А. Я., Стрельцова А. А., Костарева А. А. Гипертрофическая кардиомиопатия: современные возможности фармакологических подходов к лечению. Терапевтический архив. 2019;91(9):129-36. doi:10.26442/00403660.2019.09.000137.

Gudkova AY, Streltsova AA, Kostareva AA. Hypertrophic cardiomyopathy: modern aspects of pharmacologic treatment. Terapevticheskii arkhiv. 2019;91(9):129-36. doi:10.26442/00403660.2019.09.000137.

329

Ammirati E, Contri R, Coppini R, et al. Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. Eur J Heart Fail. 2016;18(9):1106-18. doi:10.1002/ejhf.541.

330

Spicer RL, Rocchini AP, Crowley DC, et al. Hemodynamic effects of verapamil in children and adolescents with hypertrophic cardiomyopathy. Circulation. 1983;67(2):413-20. doi:10.1161/01.cir.67.2.413.

331

Flamm MD, Harrison DC, Hancock EW. Muscular subaortic stenosis. Prevention of outflow obstruction with propranolol. Circulation. 1968;38(5):846-58. doi:10.1161/01.cir.38.5.846.

332

Sherrid MV. Drug Therapy for Hypertrophic Cardiomypathy: Physiology and Practice. Curr Cardiol Rev. 2016;12(1):52-65. doi:10.2174/1573403x1201160126125403.

333

Sherrid MV, Gunsburg D, Sharma A. Medical treatment of hypertrophic cardiomyopathy. Curr Cardiol Rep. 2000;2(2):148-53. doi:10.1007/s11886-000-0012-7.

334

Sherrid MV, Barac I, McKenna WJ, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;45(8):1251-8. doi:10.1016/j.jacc.2005.01.012.

335

Sherrid MV, Shetty A, Winson G, et al. Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with β-blockade or verapamil. Circ Heart Fail. 2013;6(4):694-702. doi:10.1161/CIRCHEARTFAILURE.112.000122.

336

Adelman AG, Shah PM, Gramiak R, Wigle ED. Long-term propranolol therapy in muscular subaortic stenosis. Br Heart J. 1970;32(6):804-11. doi:10.1136/hrt.32.6.804.

337

Bonow RO, Dilsizian V, Rosing DR, et al. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects. Circulation. 1985;72(4):853-64. doi:10.1161/01.cir.72.4.853.

338

Bonow RO, Rosing DR, Epstein SE. The acute and chronic effects of verapamil on left ventricular function in patients with hypertrophic cardiomyopathy. Eur Heart J. 1983;4, Suppl F:57-65. doi:10.1093/eurheartj/4.suppl_f.57.

339

Gistri R, Cecchi F, Choudhury L, et al. Effect of verapamil on absolute myocardial blood flow in hypertrophic cardiomyopathy. Am J Cardiol. 1994;74(4):363-8. doi:10.1016/0002-9149(94)90404-9.

340

Rosing DR, Condit JR, Maron BJ, et al. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: III. Effects of long-term administration. Am J Cardiol. 1981;48(3):545-53. doi:10.1016/0002-9149(81)90086-2.

341

Rosing DR, Kent KM, Maron BJ, Epstein SE. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status. Circulation. 1979;60(6):1208-13. doi:10.1161/01.cir.60.6.1208.

342

Said SM, Schaff HV, Abel MD, Dearani JA. Transapical approach for apical myectomy and relief of midventricular obstruction in hypertrophic cardiomyopathy. J Card Surg. 2012;27(4):443-8. doi:10.1111/j.1540-8191.2012.01475.x.

343

Shah A, Duncan K, Winson G, et al. Severe symptoms in mid and apical hypertrophic cardiomyopathy. Echocardiography. 2009;26(8):922-33. doi:10.1111/j.1540-8175.2009.00905.x.

344

Maron MS, Rowin EJ, Olivotto I, et al. Contemporary Natural History and Management of Nonobstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2016;67(12):1399-409. doi:10.1016/j.jacc.2016.01.023.

345

McMurray JJ, Adamopoulos S, Anker SD, et al.; ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787-847. doi:10.1093/eurheartj/ehs104. Erratum in: Eur Heart J. 2013;34(2):158.

346

Сафрыгина Ю. В., Габрусенко С. А., Овчинников А. Г. и др. Сердечные натрийуретические пептиды в плазме больных гипертрофической кардиомиопатией. Кардиология. 2007;47(5):50-7.

Safrygina YuV, Gabrusenko SA, Ovchinnikov AG, et al. Cardiac natriuretic peptides in patients with hypertrophic cardiomyopathy. Kardiologiia. 2007;47(5):50-7.

347

Braunwald E, Lambrew CT, Rockoff SD, et al. Idiopathic hypertrophic subaortic stenosis. I. A description of the disease based upon an analysis of 64 patients. Circulation. 1964;30:Suppl 4:3-119. doi:10.1161/01.cir.29.5s4.iv-3.

348

Okeie K, Shimizu M, Yoshio H, et al. Left ventricular systolic dysfunction during exercise and dobutamine stress in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2000;36(3):856-63. doi:10.1016/s0735-1097(00)00818-4.

349

Epstein SE, Rosing DR. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation. 1981;64(3):437-41. doi:10.1161/01.cir.64.3.437.

350

Shimada YJ, Passeri JJ, Baggish AL, et al. Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. JACC Heart Fail. 2013;1(6):480-7. doi:10.1016/j.jchf.2013.09.001.

351

Udelson JE, Bonow RO, O'Gara PT, et al. Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy. Circulation. 1989;79(5):1052-60. doi:10.1161/01.cir.79.5.1052.

352

Wilmshurst PT, Thompson DS, Juul SM, et al. Effects of verapamil on haemodynamic function and myocardial metabolism in patients with hypertrophic cardiomyopathy. Br Heart J. 1986;56(6):544-53. doi:10.1136/hrt.56.6.544.

353

Argulian E, Messerli FH, Aziz EF, et al. Antihypertensive therapy in hypertrophic cardiomyopathy. Am J Cardiol. 2013;111(7):1040-5. doi:10.1016/j.amjcard.2012.12.026.

354

Olivotto I, Cecchi F, Poggesi C, Yacoub MH. Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging. Circ Heart Fail. 2012;5(4):535-46. doi:10.1161/CIRCHEARTFAILURE.112.967026.

355

Robinson K, Frenneaux MP, Stockins B, et al. Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J Am Coll Cardiol. 1990;15(6):1279-85. doi:10.1016/s0735-1097(10)80014-2.

356

Olivotto I, Cecchi F, Casey SA, et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001;104(21):2517-24. doi:10.1161/hc4601.097997.

357

Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation. 1995;92(4):785-9. doi:10.1161/01.cir.92.4.785.

358

Camm AJ, Lip GY, De Caterina R, et al.; ESC Committee for Practice Guidelines-CPG; Document Reviewers. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation–developed with the special contribution of the European Heart Rhythm Association. Europace. 2012;14(10):1385-413. doi:10.1093/europace/eus305.

359

Camm CF, Camm AJ. Atrial Fibrillation and Anticoagulation in Hypertrophic Cardiomyopathy. Arrhythm Electrophysiol Rev. 2017;6(2):63-8. doi:10.15420/aer.2017.4.2.

360

Di Cori A, Lilli A, Zucchelli G, Zaca V. Role of cardiac electronic implantable device in the stratification and management of embolic risk of silent atrial fibrillation: are all atrial fibrillations created equal? Expert Rev Cardiovasc Ther. 2018;16(3):175-81. doi:10.1080/14779072.2018.1438267.

361

van Velzen HG, Theuns DA, Yap SC, et al. Incidence of Device-Detected Atrial Fibrillation and Long-Term Outcomes in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol. 2017;119(1):100-5. doi:10.1016/j.amjcard.2016.08.092.

362

Brambatti M, Connolly SJ, Gold MR, et al.; ASSERT Investigators. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation. 2014;129(21):2094-9. doi:10.1161/CIRCULATIONAHA.113.007825.

363

European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369-429. doi:10.1093/eurheartj/ehq278. Erratum in: Eur Heart J. 2011;32(9):1172.

364

Miller CAS, Maron MS, Estes NAM III, et al. Safety, Side Effects and Relative Efficacy of Medications for Rhythm Control of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Am J Cardiol. 2019;123(11):1859-62. doi:10.1016/j.amjcard.2019.02.051.

365

Schaufelberger M. Cardiomyopathy and pregnancy. Heart. 2019;105(20):1543-51. doi:10.1136/heartjnl-2018-313476.

366

Azarbal F, Singh M, Finocchiaro G, et al. Exercise capacity and paroxysmal atrial fibrillation in patients with hypertrophic cardiomyopathy. Heart. 2014;100(8):624-30. doi:10.1136/heartjnl-2013-304908.

367

Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093-100. doi:10.1378/chest.10-0134.

368

Lee HJ, Kim HK, Jung JH, et al. Novel Oral Anticoagulants for Primary Stroke Prevention in Hypertrophic Cardiomyopathy Patients With Atrial Fibrillation. Stroke. 2019;50(9):2582-6. doi:10.1161/STROKEAHA.119.026048.

369

Dominguez F, Climent V, Zorio E, et al. Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation. Int J Cardiol. 2017;248:232-8. doi:10.1016/j.ijcard.2017.08.010.

370

Li B, Sun C, Qin F, et al. Could direct oral anticoagulants be an alternative to vitamin K antagonists in patients with hypertrophic cardiomyopathy and atrial fibrillation? Int J Cardiol. 2018;256:39. doi:10.1016/j.ijcard.2017.10.113.

371

Lozier MR, Sanchez AM, Lee JJ, et al. Thromboembolic Outcomes of Different Anticoagulation Strategies for Patients with Atrial Fibrillation in the Setting of Hypertrophic Cardiomyopathy: A Systematic Review. J Atr Fibrillation. 2019;12(4):2207. doi:10.4022/jafib.2207.

372

Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-62. doi:10.1016/S0140-6736(13)62343-0.

373

Connolly SJ, Ezekowitz MD, Yusuf S, et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51. doi:10.1056/NEJMoa0905561. Erratum in: N Engl J Med. 2010;363(19):1877.

374

Gómez-Outes A, Terleira-Fernández AI, Calvo-Rojas G, et al. Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups. Thrombosis. 2013;2013:640723. doi:10.1155/2013/640723.

375

Клинические рекомендации. Фибрилляция предсердий. Москва, 2017. 65 с. https://racvs.ru/clinic/files/2017/Atrial-Fibrillation.pdf.

Clinical recommendations. Atrial fibrillation. Moscow, 2017. 65 p. https://racvs.ru/clinic/files/2017/Atrial-Fibrillation.pdf.

376

ACTIVE Investigators, Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360(20):2066-78. doi:10.1056/NEJMoa0901301.

377

Бокерия Л. А., Бокерия О.Л., Меликулов А. Х. и др. Хирургическое лечение фибрилляции предсердий: современное состояние проблемы. Анналы аритмологии. 2009;6(2):5-11.

Bockeria LA, Bockeria OL, Melikulov AH, et al. Surgical treatment for atrial fibrillation: state of the art. Annals of Arrhythmology. 2009;6(2):5-11.

378

Nishimura RA, Schaff HV. Septal myectomy for patients with hypertrophic cardiomyopathy: A new paradigm. J Thorac Cardiovasc Surg. 2016;151(2):303-4. doi:10.1016/j.jtcvs.2015.09.068.

379

Swistel DG, Balaram SK. Surgical myectomy for hypertrophic cardiomyopathy in the 21st century, the evolution of the "RPR" repair: resection, plication, and release. Prog Cardiovasc Dis. 2012;54(6):498-502. doi:10.1016/j.pcad.2012.03.001.

380

Swistel DG, Sherrid MV. The surgical management of obstructive hypertrophic cardiomyopathy: the RPR procedure-resection, plication, release. Ann Cardiothorac Surg. 2017;6(4):423-5. doi:10.21037/acs.2017.06.03.

381

Veselka J, Jensen MK, Liebregts M, et al. Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry. Eur Heart J. 2016;37(19):1517-23. doi:10.1093/eurheartj/ehv693.

382

Afanasyev AV, Bogachev-Prokophiev AV, Kashtanov MG, et al. Myectomy versus alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy. Interact Cardiovasc Thorac Surg. 2020;31(2):158-65. doi:10.1093/icvts/ivaa075.

383

Bogachev-Prokophiev A, Afanasyev A, Zheleznev S, et al. Mitral valve repair or replacement in hypertrophic obstructive cardiomyopathy: a prospective randomized study. Interact Cardiovasc Thorac Surg. 2017;25(3):356-62. doi:10.1093/icvts/ivx152.

384

Bogachev-Prokophiev A, Afanasyev AV, Zheleznev S, et al. Septal Myectomy With Vs Without Subvalvular Apparatus Intervention in Patients With Hypertrophic Obstructive Cardiomyopathy: A Prospective Randomized Study. Semin Thorac Cardiovasc Surg. 2019;31(3):424-31. doi:10.1053/j.semtcvs.2019.01.011.

385

Afanasyev A, Bogachev-Prokophiev A, Lenko E, et al. Myectomy with mitral valve repair versus replacement in adult patients with hypertrophic obstructive cardiomyopathy: a systematic review and meta-analysis. Interact Cardiovasc Thorac Surg. 2019;28(3):465-72. doi:10.1093/icvts/ivy269.

386

Гурщенков А. В., Сухова И. В., Зайцев В. В. и др. Пятилетний опыт использования мобилизации сердца при септальной миоэктомии. Кардиология и сердечно-сосудистая хирургия. 2018;11(4):54-8. doi:10.17116/kardio201811454.

Gurshenkov AV, Sukhova IV, Zaitsev VV, et al. Five years of experience in the use of cardiac mobilization in septal myoectomy. Cardiology and cardiovascular surgery. 2018;11(4):54-8. doi:10.17116/kardio201811454.

387

Agarwal S, Tuzcu EM, Desai MY, et al. Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;55(8):823-34. doi:10.1016/j.jacc.2009.09.047.

388

Alam M, Dokainish H, Lakkis NM. Hypertrophic obstructive cardiomyopathy-alcohol septal ablation vs. myectomy: a meta-analysis. Eur Heart J. 2009;30(9):1080-7. doi:10.1093/eurheartj/ehp016.

389

Swistel DG, Balaram SK. Resection, Plication, Release – the RPR procedure for obstructive hypertrophic cardiomyopathy. Anadolu Kardiyol Derg. 2006;6 Suppl 2:31-6.

390

Каштанов М. Г., Чернышев С. Д., Кардапольцев Л. В. и др. Этаноловая септальная аблация в лечении обструктивной гипертрофической кардиомиопатии: отбор пациентов и рациональность ее применения. Патология кровообращения и кардиохирургия. 2017;21(1):104-16.

Kashtanov MG, Chernyshev SD, Kardapoltsev LV, et al. Ethanol septal ablation in the treatment of obstructive hypertrophic cardiomyopathy: patient selection and the rationality of its use. Pathology of blood circulation and cardiac surgery. 2017;21(1):104-16.

391

Batzner A, Schäfers HJ, Borisov KV, Seggewiß H. Hypertrophic obstructive cardiomyopathy – the role of myectomy and percutaneous septal ablation in drug-refractory disease. Dtsch Arztebl Int. 2019;116:47-53. doi:10.3238/arztebl.2019.0047.

392

Сухов В. К., Шлойдо Е. А., Шубенок Д. А. и др. Спиртовая септальная абляция при обструктивной гипертрофической кардиомиопатии. Международный журнал интервенционной кардиоангиологии. 2013;(35):75.

Sukhov VK, Shloydo EA, Shubenok DA, et al. Alcohol septal ablation in obstructive hypertrophic cardiomyopathy. International Journal of Interventional Cardioangiology. 2013;(35):75.

393

Schaff HV, Dearani JA, Ommen SR, et al. Expanding the indications for septal myectomy in patients with hypertrophic cardiomyopathy: results of operation in patients with latent obstruction. J Thorac Cardiovasc Surg. 2012;143(2):303-9. doi:10.1016/j.jtcvs.2011.10.059.

394

McCully RB, Nishimura RA, Tajik AJ, et al. Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy. Circulation. 1996;94(3):467-71. doi:10.1161/01.cir.94.3.467.

395

Orme NM, Sorajja P, Dearani JA, et al. Comparison of surgical septal myectomy to medical therapy alone in patients with hypertrophic cardiomyopathy and syncope. Am J Cardiol. 2013;111(3):388-92. doi:10.1016/j.amjcard.2012.10.014.

396

Halpern DG, Swistel DG, Po JR, et al. Echocardiography before and after resect-plicate-release surgical myectomy for obstructive hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2015;28(11):1318-28. doi:10.1016/j.echo.2015.07.002.

397

Kaple RK, Murphy RT, DiPaola LM, et al. Mitral valve abnormalities in hypertrophic cardiomyopathy: echocardiographic features and surgical outcomes. Ann Thorac Surg. 2008;85(5):1527-35, 1535.e1-2. doi:10.1016/j.athoracsur.2008.01.061.

398

Kofflard MJ, van Herwerden LA, Waldstein DJ, et al. Initial results of combined anterior mitral leaflet extension and myectomy in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 1996;28(1):197-202. doi:10.1016/0735-1097(96)00103-9.

399

Schoendube FA, Klues HG, Reith S, et al. Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mitral apparatus. Circulation. 1995;92(9 Suppl):II122-7. doi:10.1161/01.cir.92.9.122.

400

Steggerda RC, Damman K, Balt JC, et al. Periprocedural complications and long-term outcome after alcohol septal ablation versus surgical myectomy in hypertrophic obstructive cardiomyopathy: a single-center experience. JACC Cardiovasc Interv. 2014;7(11):1227-34. doi:10.1016/j.jcin.2014.05.023.

401

Богачев-Прокофьев А. В., Железнев С. И., Фоменко М. С. и др. Эффективность расширенной миоэктомии у пациентов с желудочковой обструкцией при гипертрофической кардиомиопатии. Кардиология. 2017;57(5):38-43. doi:10.18565/cardio.2017.5.38-43.

Bogachev-Prokophiev AV, Zheleznev SI, Fomenko MS, et al. Efectiveness of extended myectomy in patients with hypertrophic cardiomyopathy with midventricular obstruction. Kardiologiia. 2017;57(5):38-43. doi:10.18565/cardio.2017.5.38-43.

402

Borisov KV. Right ventricle myectomy. Ann Cardiothorac Surg. 2017;6(4):402-9. doi:10.21037/acs.2017.07.10.

403

Wehman B, Ghoreishi M, Foster N, et al. Transmitral Septal Myectomy for Hypertrophic Obstructive Cardiomyopathy. Ann Thorac Surg. 2018;105(4):1102-8. doi:10.1016/j.athoracsur.2017.10.045.

404

Бокерия Л. А. Гипертрофическая обструктивная кардиомиопатия. Анналы хирургии. 2013;(5):5-14.

Bokeria LA. Hypertrophic obstructive cardiomyopathy. Annals of Surgery. 2013;(5):5-14.

405

Takahashi J, Wakamatsu Y, Okude J, et al. Septal myectomy, papillary muscle resection, and mitral valve replacement for hypertrophic obstructive cardiomyopathy: a case report. Ann Thorac Cardiovasc Surg. 2008;14(4):258-62.

406

Cooley DA, Wukasch DC, Leachman RD. Mitral valve replacement for idiopathic hypertrophic subaortic stenosis. Results in 27 patients. J Cardiovasc Surg (Torino). 1976t;17(5):380-7.

407

Stassano P, Di Tommaso L, Triggiani D, et al. Mitral valve replacement and limited myectomy for hypertrophic obstructive cardiomyopathy: a 25-year follow-up. Tex Heart Inst J. 2004;31(2):137-42.

408

Reis RL, Bolton MR, King JF, et al. Anterion-superior displacement of papillary muscles producing obstruction and mitral regurgitation in idiopathic hypertrophic subaortic stenosis. Operative relief by posterior-superior realignment of papillary muscles following ventricular septal myectomy. Circulation. 1974;50(2 Suppl):II181-8.

409

Shimahara Y, Fujita T, Kobayashi J, et al. Combined mechanical mitral valve replacement and transmitral myectomy for hypertrophic obstructive cardiomyopathy treatment: An experience of over 20 years. J Cardiol. 2019;73(4):318-25. doi:10.1016/j.jjcc.2018.12.012.

410

Topilski I, Sherez J, Keren G, Copperman I. Long-term effects of dual-chamber pacing with periodic echocardiographic evaluation of optimal atrioventricular delay in patients with hypertrophic cardiomyopathy >50 years of age. Am J Cardiol. 2006;97(12):1769-75. doi:10.1016/j.amjcard.2006.01.040.

411

Хирманов В. Н., Юзвинкевич С. А., Домашенко А. А. и др. Отдаленные результаты лечения гипертрофической кардиомиопатии с помощью постоянной двукамерной электрокардиостимуляции. Кардиология. 2002;(8):46-7.

Khirmanov VN, Yuzvinkevich SA, Domashenko AA, et al. Long-term results of treatment of hypertrophic cardiomyopathy with permanent two-chamber pacing. Kardiologiia. 2002;(8):46-7.

412

Трешкур Т. В., Крутиков А. Н., Хирманов В. Н. и др. Внутрисердечная гемодинамика у больных с гипертрофической кардиомиопатией при лечении постоянной двухкамерной электрокардиостимуляцией. Вестник аритмологии. 1995;(4):248-9.

Treshkur TV, Krutikov AN, Khirmanov VN, et al. Intracardiac hemodynamics in patients with hypertrophic cardiomyopathy treated with permanent two-chamber pacing. Bulletin of Arrhythmology. 1995;(4):248-9.

413

Daubert C, Gadler F, Mabo P, Linde C. Pacing for hypertrophic obstructive cardiomyopathy: an update and future directions. Europace. 2018;20(6):908-20. doi:10.1093/europace/eux131.

414

Quintana E, Cox JL. Surgical management of atrial fibrillation at the time of septal myectomy. Ann Cardiothorac Surg. 2017;6(4):386-93. doi:10.21037/acs.2017.05.08.

415

Бокерия Л. А., Бокерия О. Л., Климчук И. Я., Санакоев М. К. Хирургическая коррекция обструктивной гипертрофической кардиомиопатии с SAM-синдромом и фибрилляцией предсердий. Анналы аритмологии. 2016;13(4):216-21. doi:10.15275/annaritmol.2016.4.4.

Boсkeria LA, Boсkeria OL, Klimchuk IYa, Sanakoev MK. Surgical correction of obstructive hypertrophic cardiomyopathy with sam-syndrome and atrial fibrillation. Annals of Arrhythmology. 2016;13(4):216-21. doi:10.15275/annaritmol.2016.4.4.

416

Бокерия Л. А., Тетвадзе И. В., Маленков Д. А., Санакоев М. К. Сочетанная операция миоэктомии межжелудочковой перегородки из правого желудочка и эпикардиальная криомодификация операции «лабиринт». Анналы аритмологии. 2013;10(2):64-8. doi:10.15275/annaritmol.2013.2.1.

Bockeria LA, Tetvadze IV, Malenkov DA, Sanakoev MK. Combined septal myectomy from the right ventricle and epicardial modification of cryo-maze procedure. Annals of Arrhythmology. 2013;10(2):64-8. doi:10.15275/annaritmol.2013.2.1.

417

Bogachev-Prokophiev AV, Afanasyev AV, Zheleznev SI, et al. Concomitant ablation for atrial fibrillation during septal myectomy in patients with hypertrophic obstructive cardiomyopathy. J Thorac Cardiovasc Surg. 2018;155(4):1536-42.e2. doi:10.1016/j.jtcvs.2017.08.063.

418

Monserrat L, Elliott PM, Gimeno JR, et al. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol. 2003;42(5):873-9. doi:10.1016/s0735-1097(03)00827-1.

419

Task Force for the Diagnosis and Management of Syncope; European Society of Cardiology (ESC); European Heart Rhythm Association (EHRA); Heart Failure Association (HFA); Heart Rhythm Society (HRS), Moya A, Sutton R, Ammirati F, et al. Guidelines for the diagnosis and management of syncope (version 2009). Eur Heart J. 2009;30(21):2631-71. doi:10.1093/eurheartj/ehp298.

420

Sherrid MV, Massera D. Risk Stratification and Hypertrophic Cardiomyopathy Subtypes. J Am Coll Cardiol. 2019;74(19):2346-9. doi:10.1016/j.jacc.2019.09.020.

421

Mentias A, Raeisi-Giglou P, Smedira NG, et al. Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Preserved Systolic Function. J Am Coll Cardiol. 2018;72(8):857-70. doi:10.1016/j.jacc.2018.05.060. Erratum in: J Am Coll Cardiol. 2018;72(14):1761.

422

Трансплантация сердца и механическая поддержка кровообращения. Национальные клинические рекомендации. 2016. 115 с. https://sudact.ru/law/natsionalnye-klinicheskie-rekomendatsii-transplantatsiia-serdtsa-i-mekhanicheskaia/natsionalnye-klinicheskie-rekomendatsii/.

Heart transplantation and mechanical circulatory support. National clinical guidelines. 2016. 115 p. https://sudact.ru/law/natsionalnye-klinicheskie-rekomendatsii-transplantatsiia-serdtsa-i-mekhanicheskaia/natsionalnye-klinicheskie-rekomendatsii/.

423

Topilsky Y, Pereira NL, Shah DK, et al. Left ventricular assist device therapy in patients with restrictive and hypertrophic cardiomyopathy. Circ Heart Fail. 2011;4(3):266-75. doi:10.1161/CIRCHEARTFAILURE.110.959288.

424

Biagini E, Spirito P, Leone O, et al. Heart transplantation in hypertrophic cardiomyopathy. Am J Cardiol. 2008;101(3):387-92. doi:10.1016/j.amjcard.2007.09.085.

425

Диагностика и лечение сердечно-сосудистых заболеваний при беременности 2018. Национальные рекомендации. Российский кардиологический журнал. 2018;(3):91-134. doi:10.15829/1560-4071-2018-3-91-134.

Diagnosis and treatment of cardiovascular diseases during pregnancy 2018. National guidelines. Russian Journal of Cardiology. 2018;(3):91-134. doi:10.15829/1560-4071-2018-3-91-134.

426

Goland S, van Hagen IM, Elbaz-Greener G, et al. Pregnancy in women with hypertrophic cardiomyopathy: data from the European Society of Cardiology initiated Registry of Pregnancy and Cardiac disease (ROPAC). Eur Heart J. 2017;38(35):2683-90. doi:10.1093/eurheartj/ehx189.

427

Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al.; ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39(34):3165-241. doi:10.1093/eurheartj/ehy340.

428

Bowyer L. The Confidential Enquiry into Maternal and Child Health (CEMACH). Saving Mothers’ Lives: reviewing maternal deaths to make motherhood safer 2003-2005. The Seventh Report of the Confidential Enquiries into Maternal Deaths in the UK. Obstet. Med. 2008;1(1):54-54. doi:10.1258/om.2008.080017.

429

Billebeau G, Etienne M, Cheikh-Khelifa R, et al. Pregnancy in women with a cardiomyopathy: Outcomes and predictors from a retrospective cohort. Arch Cardiovasc Dis. 2018;111(3):199-209. doi:10.1016/j.acvd.2017.05.010.

430

Krul SP, van der Smagt JJ, van den Berg MP, et al. Systematic review of pregnancy in women with inherited cardiomyopathies. Eur J Heart Fail. 2011;13(6):584-94. doi:10.1093/eurjhf/hfr040.

431

Tromp CH, Nanne AC, Pernet PJ, et al. Electrical cardioversion during pregnancy: safe or not? Neth Heart J. 2011;19(3):134-6. doi:10.1007/s12471-011-0077-5.

432

Maron MS, Finley JJ, Bos JM, et al. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation. 2008;118(15):1541-9. doi:10.1161/CIRCULATIONAHA.108.781401.

433

Burton H, Alberg C, Stewart A. Heart to Heart: Inherited Cardiovascular Conditions Services – A Needs Assessment and Service Review. 2009. 163 p. ISBN: 978-1-907198-01-4.

434

Canepa M, Pozios I, Vianello PF, et al. Distinguishing ventricular septal bulge versus hypertrophic cardiomyopathy in the elderly. Heart. 2016;102(14):1087-94. doi:10.1136/heartjnl-2015-308764.

435

Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124. doi:10.1136/bmj.d124.

436

Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011;57(2):173-80. doi:10.1016/j.jacc.2010.09.024.

The authors declare that there are no conflicts of interest present.